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Sammendrag 
I 
 
 
 
 
Sammendrag 
 
Brystkreft er den hyppigste kreftsykdommen blant kvinner. Lokalavansert brystkreft 
utgjør omtrent 10% av alle brystkrefttilfeller og omfatter en heterogen pasientgruppe 
med ulike prognoser. Pasienter med lokalavansert brystkreft får ofte kjemoterapi før 
kirurgisk fjerning av tumor, såkalt neoadjuvant kjemoterapi, for å redusere størrelsen på 
tumoren. Det er stor variasjon i behandlingsrespons for denne pasientgruppen, og det er 
derfor behov for å utvikle målrettet og individualisert behandling, samt metoder for 
oppfølging av behandlingsrespons.  
 
Metabolomics er en systematisk analyse av småmolekylære forbindelser (metabolitter) i 
biologiske prøver. Den metabolske profilen til brystkreftvev er vist å korrelere med 
viktige kliniske parametere, for eksempel tumorgrad, hormonreseptorstatus og 
lymfeknutespredning. Magnetisk resonans (MR) spektroskopi er en metode som kan gi 
en detaljert beskrivelse av metabolittprofilen i vevet. En fordel med denne metoden er at 
vevsprøven er intakt etter analysen slik at den samme vevsprøven kan analyseres videre 
med andre metoder, for eksempel immunohistokjemi, genuttrykk- eller proteinanalyse.  
 
En sentral gruppe metabolitter innenfor brystkreftforskning er kolinforbindelser. Disse 
metabolittene er viktig for celledeling, signaloverføring, lipidmetabolisme og cellens 
membranstruktur. Laktat er en annen viktig metabolitt som inngår i 
energimetabolismen. I dette arbeidet ble vevsprøver fra pasienter med lokalavansert 
brystkreft analysert ved bruk av MR spektroskopi for prediksjon av behandlingsrespons 
og overlevelse. I tillegg undersøkte vi rollen til glycerophosphodiester 
phosphodiesterase (GDPD) i regulering av kolinforbindelser.  
 
 
 
 
Sammendrag 
II 
 
Alle pasienter hadde en effekt av behandlingen som ble gitt, og nesten alle fikk en 
reduksjon i tumorstørrelse etter behandling. Resultatene viste ingen metabolske 
forskjeller mellom pasienter med klinisk god eller dårlig behandlingsrespons. 
Resultatene viser derimot at de metabolske forandringene som skjer under neoadjuvant 
kjemoterapi er forskjellig i pasienter som overlever mer enn fem år og de som dør før 
fem år. Høyere nivå av laktat, glycine og kolinforbindelser etter behandling var 
forbundet med dårlig prognose. Analysene av GDPD5 tyder på at enzymet er involvert i 
reguleringen av kolinmetabolismen, men dets rolle for bruk i målrettet terapi er fortsatt 
uklart og nye studier må til for å undersøke dette.  
 
MR metabolomics kan brukes til å undersøke metabolske forandringer under 
neoadjuvant kjemoterapi behandling og kan identifisere viktige metabolitter for 
prediksjon av overlevelse hos pasienter med lokalavansert brystkreft. 
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Summary 
 
Breast cancer is the most frequent cancer disease among women globally. Locally 
advanced breast cancer (LABC) constitutes a heterogeneous group of patients with 
variable prognosis. Today’s treatment decision is predominately based on clinical 
assessment, histopathological evaluation, and hormone receptor and lymph node status. 
So far, these data are not sufficient for designing a proper personalized treatment or 
accurately predicting treatment response and survival. Molecular characterization of 
tumors may help stratifying patients for individualized treatment, thereby achieving 
better prognosis. 
 
Magnetic resonance (MR) metabolomics analyses assess the downstream products of 
gene and protein expressions, i.e. the metabolites, and have shown to provide both 
predictive and prognostic information for several types of cancers. Proton high 
resolution magic angle spinning (1H HR MAS) MR spectroscopy is a non-destructive 
and high-throughput technique that provides highly resolved MR spectra from 
biological tissue. Recently, altered cell metabolism is suggested as a new emerging 
hallmark of cancer. Choline phospholipid metabolism is involved in cell signaling, lipid 
metabolism, and the structural integrity of the cell membrane. Several MRS studies 
have suggested the total choline-containing metabolite (tCho) level as an in vivo 
biomarker for diagnosis and treatment evaluation of breast cancer. Reprogramming of 
energy metabolism and activation of tumor hypoxic response are commonly observed in 
cancers, and can be characterized by high lactate production.     
 
In this thesis, multivariate data analyses and metabolite quantification of 1H HR MAS 
MRS data were performed to investigate the potential of metabolomics for prediction of 
clinical response and long-term survival in LABC patients receiving neoadjuvant 
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chemotherapy (NAC). In addition, the role of glycerophosphodiester phosphodiesterase 
(GDPD) in choline phospholipid metabolism of human breast cancer was investigated.  
 
All patients had a metabolic response to NAC and almost all patients had a reduction in 
tumor size. Our results show no clear differences in metabolic responses to NAC 
between patients with partial response and stable disease and no significant multivariate 
models for prediction of clinical response by MR metabolomics data. In general, all 
patients experienced a decrease in tCho levels. It is possible that a cohort including also 
patients with progressive disease would reveal clearer differences in the metabolite 
profiles between the clinical response groups. This thesis demonstrates that MR 
metabolomics contain prognostic information that is associated with survival status of 
LABC patients. Increase in lactate levels as a response to NAC was associated with low 
survival rates (< 5 years), while decreased glycine and choline phospholipid metabolites 
were associated with long-term survival (≥ 5 years). The observed metabolite profiles 
consisting of higher levels of lactate, glycine, and tCho post-treatment were predictive 
of low breast cancer survival rates. 
 
GDPD5 gene expression was correlated with choline phospholipid metabolite levels and 
with CHKA and PLD1 gene expressions suggesting GDPD5 to have a role in regulation 
of choline phospholipid metabolism in human breast cancer. However, more studies are 
needed to investigate the relationship between GDPD5 and tumor malignancy, and also 
estrogen receptor status, for use as target in breast cancer treatment. 
 
In conclusion, monitoring metabolic responses to NAC by MR metabolomics may have 
the potential to assist the prediction of survival and help identify new targets for 
therapeutic treatment of breast cancer. 
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μ magnetic moment 
1H HR MAS proton high-resolution magic angle spinning 
AJCC American Joint Committee on Cancer 
AQ acquisition time 
ATCC American Type Culture Collection 
ATP adenosine triphosphate 
B0 external magnetic field 
BRCA breast cancer susceptibility gene 
CDP-choline cytidine diphosphate choline 
CHKA choline kinase alpha 
Cho free choline 
CHT-1 choline transporter-1 
CPMG Carr-Purcell-Meiboom-Gill 
CR complete response 
CT computerized tomography 
ct threshold cycle 
CTP phosphocholine cytidylyltransferase 
CV cross-validation 
EGFR epidermal growth factor receptor 
ER estrogen receptor 
ERETIC electronic reference to access in vivo concentration 
FBS fetal bovine serum 
FEC 5-flourouracil, epirubicin and cyclophosphamide 
FID free-induction decay 
GA genetic algorithm 
GDPD5 glycerophosphodiester phosphodiesterase domain containing 5 
GPC glycerophosphocholine 
GPC-PDE glycerophosphocholine phosphodiesterase 
HER2 human epidermal growth factor receptor 2 
HES hematoxylin-eosin-saffron 
HiF-1 hypoxia inducible factor-1 
HR high-resolution 
HRP horseradish peroxidase 
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I spin quantum number 
IBC inflammatory breast cancer 
IDC invasive ductal carcinoma 
ILC invasive lobular carcinoma 
LABC locally advanced breast cancer 
LDH lactate dehydrogenase 
LV latent variable 
LYSO-PLA1 lysophospholipase A1 
MAS magic angle spinning 
MCT monocarboxylate transporters 
MRI magnetic resonance imaging 
MRS magnetic resonance spectroscopy 
NAC neoadjuvant chemotherapy 
NBCG Norwegian Breast Cancer Group 
NPP6 nucleotide pyrophosphatases/phosphodiesterases 6 
OCT2 organic cation transporter-2 
PBS phosphate buffered saline 
PC phosphocholine 
PC principal component 
PCA principal component analysis 
pCR pathological complete response 
PD progressive disease  
PgR progesterone receptor 
PLA2 phospholipase A2 
PLC PtdCho-specific phospholipase C 
PLD PtdCho-specific phospholipase D 
PLS-DA partial least squares discriminant analysis 
ppm parts-per million 
PR partial response  
PtdCho phosphatidylcholine 
PULCON pulse length based concentration determination 
pw pulse width 
qRT-PCR quantitative real-time PCR 
RECIST Response Evaluation Criteria on Solid Tumors 
RF radio frequency 
RIN RNA integrity number 
ROC receiver operating characteristic 
S/N signal-to-noise ratio 
SD stable disease  
SDS-PAGE sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
T1 longitudinal relaxation time 
T2 transversal relaxation time  
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tCho choline-containing metabolites 
TE echo time 
TMS tetramethylsilane 
TNM extend of tumor (T), degree of spread to lymph nodes (N), distant metastasis (M) 
TR repetition time 
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UICC Union for International Cancer Control 
VEGF vascular endothelial growth factor 
VIP variable importance in the projection 
WHO World Health Organization 
ωr spin-rate 
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1 Introduction  
 
1.1 Breast cancer 
Breast cancer is the most frequent cancer disease among women globally with 
approximately 1.6 million new cases diagnosed in 2010 [1]. Despite improvements in 
early detection and treatment, breast cancer is still one of the leading causes of cancer-
related death among women globally with an estimated 425 000 deaths in 2010 [1]. In 
Norway, 2745 newly diagnosed breast cancer cases and 671 breast cancer deaths were 
reported for women in 2009 [2]. The incidence of breast cancer is higher in the western 
countries than in developing countries, but the mortality rate is higher in less developed 
regions of the world [3]. These differences can in part be explained by different access 
to medical facilities and treatment strategies. 
 
Factors associated with breast cancer risk can be genetic or non-genetic. Hereditary 
breast cancer accounts for 5-10% of all breast cancer cases and is mostly caused by 
germline mutations in the two first identified breast cancer susceptibility genes, BRCA1 
and BRCA2 [4]. Exposure to reproductive hormones, such as estrogen and 
progesterone, are thought to increase breast cancer risk through their influence on cell 
proliferation [5]. Many non-genetic factors associated with increased breast cancer risk 
have been identified including age, early menarche and late menopause, late age at first 
childbirth (> 35 year), no breastfeeding,  use of oral contraceptives and post-
menopausal hormones, post-menopausal obesity, alcohol consumption, and physical 
inactivity [6, 7]. 
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The female breast consists of lobules (made of lobular epithelial cells that line the milk-
producing glands), ducts (made of duct epithelial cells that line the tubes conveying 
milk secretion), fatty tissue, and connective tissue. Carcinoma originating from 
epithelial cells is the most common type of breast cancer  [8]. During cancer 
transformation normal epithelial cells lining the ducts or lobules are replaced by 
malignant atypical epithelial cells (Figure 1.1). Invasive ductal carcinoma (IDC) and 
invasive lobular carcinoma (ILC) account for approximately 80% and 10-20% of breast 
cancer cases, respectively [8].  
 
The overall 5-year breast cancer survival rate is approximately 80% for all patients, but 
is lower for advanced breast cancer [9]. Locally advanced breast cancer (LABC) 
constitutes a heterogeneous group of patients with variable prognosis and with a 5-year 
survival rate of 50-80% [10]. LABC can be defined as the most advanced stage before 
metastatic disease and constitutes approximately 10% of the newly diagnosed breast 
cancers [11]. The incidence of LABC is higher in developing countries than in western 
countries probably due to the occurrence of late-stage disease at the time of diagnosis 
[11].  
 
 
Figure 1.1: Anatomical illustration of locally advanced breast cancer (LABC). LABC can 
originate from ductal or lobular epithelial cells. The tumors are either > 5 cm or of any size with 
extension to chest wall, skin or with lymph node metastasis. The different types of metastatic 
lymph nodes are illustrated, see Table 1.1. 
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1.1.1 Staging of breast cancer  
Breast cancer staging can be defined using the TNM classification system which takes 
into consideration the extent of the tumor (T), the degree of spread to lymph nodes (N), 
and distant metastasis (M) (Table 1.1) [12]. The TNM system is used to describe the 
extent of the disease and is indeed an important prognostic factor for determining 
treatment options and survival probabilities. The TNM clinical categories are 
determined by physical examinations and imaging modalities such as mammography 
and ultrasound of the breast, and often bone scintigram, and computerized tomography 
(CT) examination of lung and liver. Based on the TNM system, the patients are divided 
into different breast cancer stages ranging from 0 to IV. Stage 0 is used to describe non-
invasive breast cancer, while stages I to III include invasive breast cancer with or 
without lymph node metastasis. Stage IV describes invasive breast cancer that has 
spread to other organs [12].  
 
There is no international standard for the staging of LABC. In general, LABC can be 
defined as T3-T4 (any N) or N2-N3 (any T) without distant metastasis (M0), which 
includes all patients of stage IIIA-C disease and a subset of stage IIB. According to the 
TNM system, inflammatory breast cancer (IBC) is considered a subgroup of LABC 
[12]. However, IBC is often discussed separately due to its distinct clinical presentation 
and poor prognosis compared to non-IBC [13]. 
  
Table 1.1 TNM clinical classification according to the AJCC/UICC [12]  
 Characteristic   
T0 No evidence of primary tumor  
T1 Tumor ≤ 2 cm in greatest dimension   
T2 Tumor > 2 cm, but ≤ 5 cm in greatest dimension  
T3 Tumor > 5 cm in greatest dimension LABC 
T4 Tumor of any size with extension to chest wall or skin or inflammatory carcinoma LABC 
N0 No regional lymph node metastasis  
N1 Metastasis in movable ipsilateral axillary lymph node(s)   
N2 Metastasis in fixed ipsilateral axillary lymph node(s) LABC 
N3 Metastasis in ipsilateral infraclavicular or supraclavicular lymph node(s) LABC 
M0 No distant metastasis  
M1 Distant metastasis  
TNM categories associated with locally advanced breast cancer (LABC) are highlighted. AJCC, 
American Joint Committee on Cancer; UICC, Union for International Cancer Control. 
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1.1.2 Prognostic and predictive factors  
Prognostic factors can predict the outcome of a disease, while predictive factors can 
predict the response to a specific treatment. The prognostic factors for LABC are similar 
to the prognostic factors for earlier stage breast cancer with tumor size, grade, and 
lymph node status being the strongest prognostic factors for breast cancer survival [14].  
 
Estrogen receptor (ER) and progesterone receptor (PgR) are ligand-dependent nuclear 
transcription factors involved in proliferative activity and reproductive development. 
Overexpression of ER and PgR is typically observed in breast cancer and is thought to 
play a major role in breast cancer progression [5]. The mechanisms behind the abnormal 
expression of these reproductive hormone receptors are still under investigation. 
Interestingly, both germline and somatic mutations in the ER gene of breast carcinomas 
are in fact rare [15]. Patients with ER and PgR positive tumors have better prognosis 
compared to patients that are negative for these hormone receptors [16].  
 
Human epidermal growth factor receptor-2 (HER2, HER-2/neu, c-erbB2) is a relatively 
newly discovered biological target for the treatment of breast cancer. HER2 is a member 
of the epidermal growth factor receptor (EGFR) family which regulates several signal 
transduction pathways of cell growth and differentiation. The expression of HER2 is 
increased in approximately 20% of breast carcinomas and is associated with increased 
proliferation, high metastatic potential and poor outcome [17, 18]. 
 
Hormone receptor status and HER2 expression are used as target for breast cancer 
treatment. Thus, they can be defined as both prognostic and predictive factors. The 
change in tumor size in response to treatment is an important predictive factor for 
treatment evaluation. In the last decade, molecular characterization by metabolic 
profiling has provided potential new factors that may play an important role in 
diagnosis, treatment evaluation, and prognosis of breast cancer [19]. 
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1.2 Treatment strategies for LABC 
The treatment regimens recommended for LABC patients vary between countries. In 
general, the patients are often treated with chemotherapy before surgery, so-called 
neoadjuvant chemotherapy (NAC), to shrink the tumor enough to make surgical 
removal possible and even allow for breast conserving surgery in exchange of a 
mastectomy. After surgery, post-operative treatment is usually given in the same way as 
for those with earlier stage breast cancer. In Norway, guidelines for treatment regimen 
of LABC are given by the Norwegian Breast Cancer Group (www.NBCG.no).  
 
1.2.1 Neoadjuvant chemotherapy (NAC) 
Primary systemic treatment (or NAC) was first described in the 1970’s [20] and is now 
well established in the treatment of LABC [10]. For LABC patients, treatment with 
NAC is given to make a tumor operable, either by mastectomy or breast-conserving 
surgery. Overall, NAC offers direct evaluation of treatment effects and the response to 
NAC has been shown to be an important predictor of survival [21, 22]. Better clinical 
and pathological response to NAC is associated with prolonged recurrence-free survival 
[21, 22]. In Norway, the current standard treatment for LABC is a combination of the 
cytostatic agents 5-flourouracil, epirubicin, and cyclophosphamide (FEC) and often 
sequential treatment of FEC and a taxane substance (www.NBCG.no). 
 
Anthracyclines were discovered in the 1960’s and include doxorubicin and epirubicin 
which are among the most effective chemotherapeutic agents for the treatment of breast 
cancer. These agents predominately accumulate in neoplastic and proliferating cells 
where they are capable of inducing DNA strand breakage and apoptosis through their 
interaction with DNA binding proteins, tumor suppressor gene p53, and DNA 
intercalation [23-25]. Another relatively new recommended drug group developed in the 
1990’s for use in the treatment of breast cancer is taxane. Paclitaxel is a taxane drug that 
causes mitotic arrest by disturbing the breaking and rearranging of microtubules in the 
cells [26].  
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1.2.2 Post-operative treatment 
Post-operative treatment such as radiation, hormone, and biologic therapies are usually 
given to LABC patients. For women at high risk of recurrence, like LABC patients, the 
breast cancer survival rate has been shown to significantly improve when treated with 
radiation therapy [27]. Patients with ER positive tumors could benefit from anti-
estrogen drugs, such as tamoxifen, which can result in a reduction of recurrences and 
breast cancer death [28, 29]. Treatment with trastuzumab, a monoclonal antibody 
against HER2, can reduce the recurrence rate and mortality of breast cancer [18]. 
 
1.2.3 Clinical response evaluation  
The change in tumor size can be used as a predictive factor of a specific treatment. The 
tumor response criteria were first published by the World Health Organization (WHO) 
in 1981 (Table 1.2) [30]. In 2000, an improved and standardized response evaluation 
system was introduced, known as Response Evaluation Criteria on Solid Tumors 
(RECIST) (Table 1.2) [31]. Imaging modalities such as mammography, ultrasound, and 
magnetic resonance imaging (MRI) can be used for the evaluation of treatment 
response. MRI has been shown to correlate the best with pathological findings 
compared to clinical examination, mammography, and ultrasound [32]. However, in a 
neoadjuvant setting when the breast lesions are large (> 5 cm in greatest dimension), the 
response to treatment can be evaluated clinically using a caliper [31]. 
 
Table 1.2 Clinical response criteria for target lesions according to WHO and RECIST criteria 
[30, 31]  
 WHO* RECIST 
 Bidimensional Unidimensional 
 Product of the two largest diameters 
The longest diameter 
 
Complete response (CR) Disappearance of all target lesions Disappearance of all target lesions 
Partial response (PR) ≥ 50% decrease ≥ 30% decrease 
Stable disease (SD) < 50% decrease to < 25% increase < 30% decrease to < 20% increase 
Progressive disease (PD) ≥ 25% increase ≥ 20% increase 
* Clinical response criteria used in paper I and II. 
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1.3 The biology of cancer  
Carcinogenesis is a multistep process that involves essential genomic alternations that 
collectively dictate malignant growth. Six hallmarks of cancer have been suggested as 
novel characteristics of cancer cells, including being self-sufficient in growth signals, 
insensitive to anti-growth signals, limitless replicative potential, evading apoptosis, 
sustained angiogenesis, and tissue invasion [33]. Two emerging physiological features, 
reprogramming of energy metabolism and evading immune destruction, have recently 
been added to the list [34].  
 
1.3.1 Tumor glycolysis 
Cancer cells have the ability to adjust their energy metabolism in order to promote rapid 
and uncontrolled cell proliferation. Glycolysis is a metabolic process in which glucose 
is converted into pyruvate to produce energy in the form of adenosine triphosphate 
(ATP). The total number of ATP per glucose molecule depends on the metabolic fate of 
pyruvate, which in normal cells depend on oxygen availability. In non-proliferating 
cells under condition of sufficient oxygen supply, pyruvate is completely oxidized in the 
mitochondria through oxidative phosphorylation which results in high ATP production 
(Figure 1.2). During anaerobic glycolysis, only a minimum number of ATP is produced 
by converting pyruvate to lactate. In cancer cells, most pyruvate is converted to lactate 
regardless of the oxygen levels, so-called aerobic glycolysis. This glycolytic switch in 
cancer cells was first described by Warburg in the 1950’s [35].  
 
Figure 1.2: Energy metabolism in non-
proliferating and tumor cells. In case of low 
oxygen supply, normal cells can undergo 
anaerobic glycolysis and generate lactate 
instead of mitochondrial oxidative 
phosphorylation to allow for glycolysis to 
continue. Tumor cells tend to convert most 
glucose to lactate regardless of the oxygen 
supply. This reprogramming of energy 
metabolism appears to promote tumor growth.   
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Lactate
+O2
-O2 +O2/-O2
Lactate
Tumor cellsNon-proliferating cells
Aerobic
glycolysis
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Oxidative 
phosphorylation
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It is not fully understood why cancer cells prefer the lower efficiency of ATP 
production than mitochondrial oxidative phosphorylation. It has been suggested that 
aerobic glycolysis protects cancer cells from acid-induced cell toxicity and is an 
adaption to intermittent hypoxia in pre-malignant lesions [36]. In addition, increased 
glycolysis has been shown to facilitate the uptake and incorporation of nutrients needed 
for cell proliferation [37]. Also, glycolytic intermediates are involved in various 
biosynthetic pathways that facilitate cell proliferation [37, 38]. The metabolite glycine is 
an amino acid involved in the nucleotide and protein synthesis, and is derived from the 
glycolytic intermediate 3-phosphoglycerate, but can also be synthesized from choline 
through the glycine-betaine pathway. The levels of glycine and lactate have been 
associated with malignancy and prognosis in different types of cancers [39-45]. 
However, the molecular mechanisms behind the influence of glycine and lactate on 
malignant behavior of cancer cells are not fully understood.  
 
1.3.2 Tumor hypoxia and angiogenesis 
Normal cells have the capacity to adapt to conditions of low oxygen supply by 
increasing their oxygenation through the activation of hypoxia inducible factor-1 (HiF-
1) transcription factor. HiF-1 regulates multiple downstream genes involved in glucose 
transportation, the glycolytic pathway, oxygen capacity, and angiogenesis (e.g. vascular 
endothelial growth factor, VEGF) [46-49]. Hypoxia is typically observed in solid 
tumors as a result of poor blood supply due to either large tumor size or chaotic and 
dysfunctional vasculature. Tumor cells appear to have taken advantage of the hypoxic 
response system to facilitate cell proliferation and angiogenesis which are required for 
tumor growth and metastasis [50]. Furthermore, HIF-1 plays a regulative role in the 
production and transportation of lactate by influencing the expression of lactate 
dehydrogenase (LDH) and monocarboxylate transporters (MCT) [51, 52]. Thus, lactate 
may act as a downstream maker for aerobic glycolysis and hypoxic response in tumors.  
 
1.3.3 Tumor phospholipid metabolism  
Choline phospholipid metabolism, also known as the Kennedy pathway, is the major 
biosynthetic pathway of de novo phosphatidylcholine (PtdCho) synthesis in mammalian 
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cells. PtdCho is the most abundant phospholipid in the cells and forms together with 
other lipids the characteristic bilayer structure of the cell membrane. Choline-containing 
metabolites (tCho) include glycerophosphocholine (GPC), phosphocholine (PC), and 
free choline (Cho), and are involved in cell signaling, lipid metabolism, and the 
structural integrity of the cell membrane. PC is both a precursor and a breakdown 
product of PtdCho that can act as a secondary messenger with the ability to stimulate 
cell proliferation through several growth factors [53], while GPC is a breakdown 
product of PtdCho that may reflect phospholipid membrane turnover [54]. GPC is also 
an abundant osmoprotective osmolyte that can protect intracellular macromolecules 
from being denatured during hypertonic stress in kidney cells [55]. Cho is derived from 
the diet, but it is also a breakdown product of GPC that is used to synthesize PC. 
However, the daily requirement of Cho from dietary sources are not well defined [56].    
 
Choline phospholipid metabolism is changed in most cancers, including breast cancer 
[57, 58]. The tCho levels detected with in vivo MR spectroscopy have been suggested as 
a biomarker for the diagnosis and treatment evaluation of breast cancer [58-62]. 
However, the molecular mechanisms behind the changes in choline phospholipid 
metabolism observed within breast cancer are not fully understood. The regulation of 
choline phospholipid metabolism can be affected by growth factor stimulation, 
cytokines, hypoxic and inflammatory responses, and oncogenic signaling [63-67]. 
Choline phospholipid metabolism is a complex pathway controlled by several 
regulatory enzymes (Figure 1.3). Changes in the expression of genes and enzymes 
involved in the biosynthetic and catabolic pathways of choline phospholipid 
metabolism, including choline kinase alpha (CHKA), PtdCho-specific phospholipase D 
(PLD), and PtdCho-specific phospholipase C (PLC), have been found in different types 
of cancers [57]. Increased activity of the choline transporters such as organic cation 
transporter-2 (OCT2) and choline transporter-1 (CHT-1) have also been identified [57]. 
CHK (E.C. 2.7.1.32) is the enzyme at the first step of the Kennedy pathway which 
regulates the phosphorylation of Cho to PC. Increased CHK activity has been detected 
in breast cancer tissue compared to normal healthy tissue [68]. CHK inhibition and 
down-regulation by RNA interference efficiently decreased cellular PC and tCho levels 
along with proliferation and tumor growth in human breast cancer cells and animal 
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models [69-72]. Phosphocholine cytidylyltransferase (CTP, E.C. 2.7.7.15), which uses 
PC as a substrate to synthesize cytidine diphosphate choline (CDP-choline), has been 
found to be underexpressed in cancer cells, leading to elevated PC levels [73]. 
 
The GPC levels in choline phospholipid metabolism is dependent on the degradation 
rate of PtdCho by the two enzymes phospholipase A2 (PLA2, E.C. 3.1.1.4) and lyso-
phospholipase A1 (LYSO-PLA1, E.C. 3.1.1.5), and the degradation of GPC itself into 
Cho and glycerol-3-phosphate by glycerophosphocholine phosphodiesterase (GPC-
PDE, E.C. 3.1.4.2). The gene expressions of PLA2 and LYSO-PLA1 correlate with 
GPC levels and can be underexpressed in malignant compared to non-malignant 
mammary epithelial cells [74]. The gene (s) responsible for GPC-PDE has not yet been 
identified. Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) is 
proposed as a candidate gene for GPC-PDE, as its expression has been shown to affect 
the enzymatic activity of GPC-PDE and consequently the GPC levels in mouse kidney 
cells [75]. To date, the role of GDPDs in choline phospholipid metabolism of human 
breast cancer have not yet been investigated. 
 
CHKA
PLC
PLD1
PLA2
GPC-PDE
Lyso-PLA1
Phosphatidylcholine        Phosphocholine
Choline Glycerophosphocholine
CTP CDP
Extracellular
Intracellular
GDPD5?
Choline
CDP-choline
 
Figure 1.3: The biosynthetic (solid lines) and catabolic (dash lines) pathways of choline 
phospholipid metabolism. GDPD5 have been suggested as a candidate gene for GPC-PDE. 
However, its role in choline phospholipid metabolism of human breast cancer is still unknown. 
CHKA, choline kinase alpha; CTP, phosphocholine cytidylyltransferase; CDP-Cho, cytidine diphosphate 
choline; CDP, diacylglycerol cholinephosphotransferase; PLA2, phospholipase A2; Lyso-PLA1, 
lysophospholipase A1;  PLD1/PLC, phosphatidylcholine-specific phospholipase D1/C; GPC-PDE, 
glycerophosphocholine phosphodiesterase; GDPD5, glycerophosphodiester phosphodiesterase domain 
containing 5. 
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1.4 Magnetic resonance spectroscopy (MRS)  
MRS is an analytical technique that provides identification and quantification of the 
metabolites. Metabolomics is the systematic study of metabolites present in a living 
system such as cells, tissues, biofluids, and organs. MRS metabolomics is emerging, 
and has provided essential information about the biochemical changes in cancers and 
other diseases [76-79]. Various metabolic biomarkers related to glycolysis and choline 
phospholipid metabolism have been reported using MRS analyses [19]. 
 
The MR spectrum is a plot of the intensity of MR signals versus the magnetic field 
frequency, usually given in parts per million (ppm). The MR signals stem from the 
interaction of radiowaves with atomic nuclei. In the presence of an external magnetic 
field (B0), atomic nuclei can absorb energy of characteristic frequencies, depending on 
the physical and chemical environment of the nucleus. In order for a nucleus to give rise 
to a MR signal, it must have a physical property called spin. The spinning nucleus 
generates a magnetic moment (μ), which is proportional to its spin quantum number (I).  
 
The most interesting nuclei for biological/medical MRS are hydrogen-1 (1H), carbon-13 
(13C), and phosphorous-31 (31P). These nuclei have a spin quantum number I = ½, i.e. 
they have two possible spin states. The spin states are of low or high energy, as the 
magnetic moment can be directed with or against the B0, respectively (Figure 1.4). A 
small majority of nuclear spins will have their magnetic moment aligned with the B0 
(designated Z-axis). This small excess of nuclei in the low energy state is the basis for 
the MR signal. By applying a radio frequency (RF) pulse, nuclei in the low energy state 
will be transferred to the high energy state. The energy difference between the low and 
Figure 1.4: In the presence of an 
external magnetic field (B0) two 
spin states exist, the magnetic 
moment (μ) of low energy state 
and high energy state.  
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high energy state is dependent on the strength of the static magnetic field, thus the 
higher field strength, the higher sensitivity. Following an RF pulse, the exited nuclei 
interact with their environment, causing them to lose their excess energy and relax back 
to equilibrium. The emitted energy can be measured, as an MR signal. The nuclei return 
to equilibrium through processes characterized by two time constants called longitudinal 
(T1) and transversal (T2) relaxation. T1 describes the time it takes for spinning nuclei to 
re-align with B0 and is dependent on the nuclei interactions with the environment. Small 
molecules have low probability for interaction due to their fast movements which result 
in long T1, while lipids and proteins have a higher probability for interaction due to their 
slow movements and thus exhibit relatively short T1. The longitudinal magnetization is 
fully recovered to its equilibrium value after about five times T1. T2 describes the time it 
takes for spinning nuclei to lose phase coherence due to magnetic field inhomogeneities 
and spin-spin relaxation arising mainly from neighboring nuclei. Large molecules, such 
as lipids and proteins, have higher interaction probability than smaller molecules and 
therefore shorter T2 values. T2 relaxation times is commonly utilized to reduce the 
signals from lipids and proteins by applying pulse sequences allowing T2- weighted MR 
spectra. 
 
MR spectra signals from solids or semisolids (e.g. tissues) are much broader than those 
from liquids (e.g. cell extracts). In liquid samples, the molecules are more mobile and 
the rapid isotropic motions of the nuclei can average the anisotropic nuclear interactions 
between the nuclei and effectively remove them from the spectrum, which results in 
spectra with narrow line width (Figure 
1.5). In solid samples, the lack of 
molecular mobility leads to anisotropic 
nuclear interactions, such as magnetic 
dipolar interactions, electric quadrupolar, 
and electron shielding interactions between 
the nuclei. These interactions result in 
large anisotropic broadenings and spectra 
with broad and overlapping signals [80].  
 
Figure 1.5: Liquid and semisolid MRS 
Liquid
Semisolid
Cell extract
Tumor
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1.4.1 High resolution magic angle spinning (HR MAS) 
For nuclei with spin quantum number I = ½ (e.g. 1H, 13C, 31P), line-narrowing in the 
MR spectra of solid samples can be achieved by imposing a motion on the nuclei which 
removes anisotropic sources of broadening. The principle of magic angle spinning 
(MAS) was first described by Andrew and Lowe in 1958 [81, 82]. Rapidly spinning of 
the solid samples at the magic angle, referring to the angle of 54.7 degrees, will mimic 
the motion of nuclei in a liquid state; resulting in sharp and highly resolved spectra, 
comparable with those from liquids.  
 
When a sample is spun about an angle to B0, the dipole interaction between the nuclei is 
dependent on the angle and the spin-rate (ωr) (Figure 1.6). When the angle is 54.7 
degrees, line broadening in solids can be reduced as some of the dipolar interactions are 
eliminated. Spinning the samples splits the broad signals into narrow lines, but it will 
also introduce low-intensity lines in the MR spectra 
that are spin-dependent, the so-called spinning 
sidebands. The intensity of the sidebands decreases 
with increasing spin rate. However, high-speed 
spinning can lead to destruction of tissue structures. 
The spin rates are chosen to eliminate the sidebands 
from the spectral region of interest. A wide range of 
spin rates, spanning from 1 Hz to 12 kHz, has been 
used for high-resolution magic angle spinning (HR 
MAS) studies. For samples analyzed with a 600 
MHz spectrometer, a spin rate of 5 kHz provides 
good spectral quality while preserving the tissue 
structures [83].  
 
Ex vivo 1H HR MAS MRS has been commercially available since the late 1990’s. The 
technique is non-destructive and requires no difficult sample preparation before 
analysis. The sample remains intact for further analyses such as histopathology, 
proteomics, and transcriptomics, thus allowing for a comprehensive and detailed study 
of the biochemical composition of the tissue. This has contributed to an improved 
Figure 1.6: Schematic illustration 
of magic angle spinning MRS 
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understanding of biochemical changes that occur in cancer and during cancer treatment. 
It has been applied to several types of human cancers including brain [84, 85], breast 
[83, 86], and prostate [87, 88]. In addition, several studies have proven 1H HR MAS 
MRS as a promising tool for diagnosis and treatment monitoring of breast cancer [89, 
90].  
 
1.4.2 Analyses of breast cancer spectra  
1H HR MAS MRS metabolite profiles of breast cancer tissue have been shown to 
correlate to parameters of clinical importance, such as tumor grade, axillary lymph node 
status, and hormone receptor status [39, 91, 92]. More than 30 metabolites have been 
detected and assigned in breast cancer tissue [83]. Part of a 1H HR MAS MR spectrum 
including some of the most studied metabolites in breast cancer tissue is shown in 
Figure 1.7. Different approaches can be used to extract information from the MR 
spectra, of which multivariate data analyses and metabolite quantification are most 
common. 
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Figure 1.7: An example of the metabolite profile of breast cancer tissue obtained by 1H HR 
MAS MRS with the spectral region that was used in paper II. The signals from water, large lipid 
residuals, and ethanol contamination were removed prior to multivariate data analyses. β-Glc, 
beta glucose; Lac, lactate; m-Ino, myo-Inositol; Cr, creatine; Gly, glycine; Tau, taurine; s-Ino, scyllo-
Inositol; GPC, glycerophosphocholine; PC, phosphocholine; Cho, free choline; Ala, alanine. 
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Multivariate data analysis 
One of the many challenges for the analysis of 1H HR MAS MR spectra is the large 
number of variables (points in the MR spectra) compared to the low number of samples 
(individuals). Multivariate statistical methods are specialized to handle such data sets, 
and can be used in a reliable manner to identify biomarkers and/or discover metabolic 
features related to the discrimination between distinct classes.  
 
Preprocessing 
Spectral preprocessing is a crucial step for building a precise and accurate multivariate 
model. There are many available methods for preprocessing the MR data. The chosen 
algorithms and parameter settings should be optimized to increase the quality of the 
spectra for multivariate modeling. Preprocessing methods including baseline correction, 
normalization, and peak alignment is usually recommended [93-95]. Mean 
normalization (also called area normalization) is a common method used to achieve an 
equal total area for each spectrum, without altering the relative intensities of the 
metabolite signals within the spectrum. This is used to compensate for individual 
differences in the samples, such as sample weight and total concentration of the 
metabolites. The peaks of MR spectra are usually not well aligned due to small 
variations in pH, temperature, and intermolecular interactions in the samples. Different 
peak alignment algorithms are available for correcting peak misalignment between the 
MR spectra, e.g. SpecAlign, icoshift, and COW [96-98]. In general, the algorithms are 
based on the insertion and deletion of spectral data points or intervals to shift regions in 
the spectrum to align with the corresponding region in a reference spectrum.  
 
Variable selection for multivariate modeling can be performed by a genetic algorithms 
(GA), which is a supervised variable selection method based on the principles of 
genetics and natural selection [99, 100]. GAs generate a population comprising 
randomly subsets of selected variables (so-called ‘chromosome’) and uses them to 
produce the next generation via reproduction and mutation. The process is repeated a 
number of generation until an optimal population consistent of the most useful subsets 
of variables has been developed.  
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Multivariate methods  
Multivariate statistic methods such as principal component analysis (PCA) and partial 
least squares discriminant analysis (PLS-DA) can be used for finding linear 
relationships between the spectral data and clinical features, such as treatment response 
[101]. PCA explains the underlying variance structure of a data set through linear 
combinations of the variables. These linear combinations are called principal 
components (PCs). The first PC (PC1) covers the maximum variation of the data 
structure, PC2 covers the second largest variation in the data, but is completely 
uncorrelated to PC1 (orthogonal direction). Each following component accounts for as 
much of the remaining variability as possible. The goal of PCA is to filter out the noise 
and redundant data to compute the most important variance structure of the data, usually 
described by the few first PCs. By plotting the PCs against each other in a score plot, 
the hidden interrelationships between different variables can be revealed. The loadings 
show how much each variable contributes to each PC. The corresponding score and 
loading plots are complementary and can be use to interpret the model. PCA is an 
unsupervised method, thus it explains the experimental data (e.g. spectral data) without 
taking into consideration any other relevant information such as clinical data. However, 
PCA is useful for the initial description of sample patterns and to detect outliers before 
carrying out more sophisticated multivariate data analyses.  
 
PLS-DA is a supervised data compression method used to detect the relationships 
between two matrices; experimental data (X) and the response variables (Y). PLS-DA 
aims to find underlying structures, called latent variables (LVs) that maximize the 
covariance between X (e.g. spectral data) and Y (e.g. treatment response). The Y-matrix 
consists of so-called “dummy variables”, classifying each sample in this example as 
either responders (-1) or non-responders (+1). In a similar manner as for PCA, the 
corresponding score and loading plots are used to identify the differences in the 
metabolite profile between classes, and subsequently to discover potential biomarkers 
for the clinical feature being investigated, see Figure 1.8. The variable importance in the 
projection (VIP) scores can be used to assist the identification of metabolites of 
importance for the classification [102].  
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Multilevel PLS-DA is an extension of the ordinary PLS-DA and can be used to 
investigate the paired structure within the different subjects [103, 104]. This analysis 
can only be applied for data with multilevel structure, i.e. when interventions are 
evaluated on the same subject. In multilevel PLS-DA, the between subject variation 
resulting from differences in age, disease state, genetics, and other factors, is separated 
from the within subject variation, thus enabling the detection of metabolic changes 
caused by the intervention. The between subject variation is described by the average of 
the two observations from one subject, whereas the within subject variation is described 
by the net difference between them [103]. After the split-up of variation, ordinary PLS-
DA classifications of the within or between subject variations can be performed. 
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Figure 1.8: A constructed example of the PLS-DA score and loading plots of responders and 
non-responders to a given treatment. The score plot shows the sample inter-relationships, thus 
similar samples are located close to each other. The loading plot shows the variable inter-
relationship and is used to interpret the reasons behind the object distribution. The scores and 
variables close to zero have no influence on the classification. In this example, the different 
classes are well discriminated by latent variable 1 (LV1). Responders have positive scores for 
LV1 and appear to have more of the metabolites lactate, taurine, GPC and Cho, while non-
responders have negative scores for LV1 higher levels of PC and β-glucose. β-Glc, beta glucose; 
Lac, lactate; Tau, taurine; GPC, glycerophosphocholine; PC, phosphocholine; Cho, free choline. 
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Validation  
Validation of multivariate models is necessary to measure the robustness of the models 
and to find the optimal dimensionality in order to avoid either overfitting or 
underfitting. Validation methods such as cross-validation, test set data, and permutation 
testing are used to assess the significance of the models. During validation the dataset is 
split in two parts; (1) a training set for model calibration and (2) a test set for model 
validation. In “leave one out” or full cross-validation only one sample is used for testing 
at a time, while the remaining samples (n-1 when there are n observations) are used for 
training. The procedure must be repeated until all samples have been validated once. 
The classification result for each sample is summed and the average represents the 
validated classification result of the model. Full cross-validation may give too optimistic 
results due to data overfitting, but is a convenient choice for data sets with low sample 
numbers (n~20). For larger data sets, validation by test set data using a defined 
percentage of the samples for testing and the remaining for training is more appropriate. 
Limiting the number of LVs is necessary in order to achieve a reliable model. The 
minimum number of LVs with the minimum classification error determined by cross-
validation can be used to optimize the number of LVs.  
 
A permutation test can be used to evaluate the statistical significance of the 
classification results [101]. Permutation testing is performed by randomly assigning the 
class labels to the samples. The permutation procedure is then repeated a number of 
times and for each time the permuted classification result is calculated. The 
classification result of the original model can then be compared to the distribution of 
classification results from the permutation procedure.   
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Metabolite quantification 
MRS is a powerful tool for quantification of metabolites present in a sample since the 
area of a given signal in the MR spectrum is proportional to the number of nuclei 
responsible for that signal. The area of a reference signal with known concentration can 
thus be used to perform absolute quantification. Accurate determination of metabolite 
concentrations can provide important biochemical information for a better 
understanding of cancer behavior and progression.  
 
Quantification of metabolites in intact breast cancer tissue is highly challenging due to 
the inherent complexity of the spectra and overlapping spectral signals from many 
metabolites. Moreover, the signals are also overlapping with the macromolecules like 
proteins and lipids. Peak integration is a simple and widely used method for peak area 
measurement in MR spectra. However, due to overlapping signals, more advanced 
model fitting methods should be applied, such as curve fitting. PeakFit (PeakFit v 4.12, 
SeaSolve Software Inc.) is a software that uses nonlinear curve fitting method to 
calculate the area of overlapping metabolite signals in a spectrum (Figure 1.9) [105]. 
Prior knowledge of the overlapping metabolite signals is essential to increase the quality 
of the fitting.  
 
 
 
 
 
 
 
Figure 1.9: Metabolite quantification of a 1H HR MAS spectrum using a peak fitting algorithm 
(e.g. PeakFit) and an ERETIC reference signal. PeakFit enables the calculation of area from 
overlapping signals and by using the ERETIC as a reference absolute concentration of 
individual metabolites can be quantified. Tau, taurine; GPC, glycerophosphocholine; PC, 
phosphocholine; Cho, free choline; ERETIC; electronic reference to access in vivo concentration. 
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The use of a reference compound for absolute quantification of metabolites in tissue 
specimens is also challenging. An ideal reference for tissue metabolite quantification 
should be highly reproducible, not react chemically with the sample, and resonate away 
from the metabolite signals of interest. Trimethylsilyl propionic acid (TSP) is 
commonly used as an internal reference in 1H HR MAS spectroscopy of tissue [106]. 
However, the hydrophobic chain of TSP tends to interact with proteins and other 
membrane components present causing an overestimation of metabolite concentrations 
[107]. TSP is therefore more suitable as a reference for cell and tissue extracts than 
tissue samples.  
 
Several studies have used the internal tissue water signal as a reference measured in an 
additional experiment without water suppression [84, 87]. However, the unsuppressed 
water signal is typically 1,000-10,000 times larger than most metabolites in the tissue. 
In addition, the relaxation time and the density of water are not constant in all tissues 
and tend to change in pathologies [108]. Therefore, extra consideration should be taken 
when evaluating the quantitative results using internal water as reference.  
 
The electronic reference to access in vivo concentration (ERETIC) published in 1999 by 
Akoka et al. is a promising alternative to the use of an internal reference [109]. The 
ERETIC signal generates a “synthetic” peak of which the MR characteristics, e.g. 
frequency, linewidth, and magnitude, are modifiable. In addition, there are no concerns 
about metabolic activity. Furthermore, the ERETIC signal can easily be moved away 
from the metabolite region of interest [109, 110]. Calibration of the ERETIC signal to a 
standard of known concentration (e.g. sucrose or creatine) then permits the use of this 
signal to quantify metabolites of interest in the sample [110-112].  
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1.5 Gene and protein analyses 
The combination of gene, protein and metabolite data is an advantage for the 
investigation of molecular pathway regulation. Quantitative real-time polymerase chain 
reaction (qRT-PCR) is a powerful and sensitive gene analysis technique for detection 
and quantification of a specific target sequence. Real-time detection of PCR products is 
made possible by using two oligonucleotide primers, forward and reverse, which are 
designed to specifically bind to the target sequence and a fluorescent molecule that 
reflects the amount of amplified PCR product. qRT-PCR data can be evaluated without 
gel electrophoresis resulting in reduced experimental time and increased throughput. 
Relative quantification of the gene expression can be determined by relating the PCR 
signal to a reference group, such as untreated controls or normal samples. 
Immunoblotting (Western blotting) allows for the identification of proteins according to 
their molecular weight by gel electrophoresis. The proteins are detected by using protein 
specific antibodies (Figure 1.10).  
    
Target protein
Membrane
Primary
protein specific antibody
HRP
Secondary
conjugated antibody
 
Figure 1.10: The principle of Western blotting analysis. Proteins are separated and transferred 
from the gel to a membrane. The membrane is exposed to the primary protein specific antibody 
in the present of a protein-rich solution to reduce non-specific binding. After several washing 
steps, the membrane is then exposed to the secondary antibody conjugated to a detectable 
molecule, e.g. horseradish peroxidise (HRP), which produces a colored band when incubated 
with the appropriate substrate. 
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2 Aims 
 
The main objective of this thesis was to explore the metabolite profiles of locally 
advanced breast cancers and the effects of NAC. More specific, the goals were to: 
 
- Evaluate whether MR metabolic profiling can assist the prediction of clinical 
treatment response in LABC patients receiving NAC  
 
- Investigate the prognostic value of the MR metabolite profile in LABC patients 
 
 
- Investigate the role of GDPDs in choline phospholipid metabolism of breast 
cancer cell lines and patient samples  
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3 Materials and methods 
 
The present thesis includes three papers presenting data from MR metabolomics, and 
gene and protein analyses of human breast cancer tissue and cell lines. A summary of 
the materials and methods used in the thesis is given in Table 3.1.  
 
Table 3.1 Materials and methods used in the papers I-III. 
 Paper I Paper II Paper III 
Materials 
 
 
Human 
samples 
Tissue samples 
n=33p/66s 
Tissue samples 
n=89p/178s 
Tissue samples 
n=19s 
 
 
Cell lines - - 
MCF-12A (n=7) 
MCF-7 (n=10) 
MDA-MB-231 (n=8) 
 
Methods 
  
Tumor cell content Histology sections Imprint cytology Imprint cytology 
 
 
 
Lac
Gly
Cho
Glu
 
Metabolomics 1H HR MAS MRS 1H HR MAS MRS 
1H HR MAS MRS/ 
1H HR MRS 
 
 
  
Gene expression - - qRT-PCR 
 
 
  
Protein expression - - Western blotting 
 
Data  
analyses  
Metabolite 
quantification 
PeakFit 
reference:  
ERETIC 
Relative intensity 
PeakFit/Integration 
reference:  
ERETIC/TSP or TMS  
 
 
  
Multivariate 
modeling PLS-DA Multilevel PLS-DA - 
 
 
 
Gene and protein 
expression 
 
- - Relative fold change 
p, pair (pre- and post-treatment); s, samples; 1H HR MAS MRS, proton high-resolution magic angle 
spinning magnetic resonance spectroscopy; qRT-PCR, quantitative real-time polymerase chain 
reaction; ERETIC, electronic reference to access in vivo concentration; TSP, trimethylsilyl propionic 
acid; TMS, tetramethylsilane; PLS-DA, partial least squares discriminant analysis. 
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3.1 Human breast cancer patients and cell lines 
The patients 
LABC patients (n=122) included in the three presented papers were enrolled in two 
large clinical studies evaluating predictive factors for response to NAC. The studies 
were approved by the Regional Ethical Committee (Norwegian Heath Region III) and 
each patient gave written informed consent. The detailed description of the inclusion 
and treatment protocols is fully described elsewhere [113, 114]. In brief, female patients 
diagnosed with invasive breast cancer stage IIIA-C and a subset of stage IIB defined as 
T3-T4 (any N) or N2-N3 (any T) without distant metastasis (M0) were enrolled in 1991-
2003. Patients with minor metastatic deposit (e.g. in the bone and liver) in addition to 
their locally advanced disease at the time of diagnosis were categorized as stage IV 
disease. These patients were also included in the studies providing they were candidates 
for surgical treatment of their primary local tumor after NAC. Patients with IBC were 
excluded in both studies due to their distinct clinical presentation and poor prognosis. 
Breast cancer tissue samples were obtained from an open biopsy procedure before NAC 
and during final surgery. The breast cancer tissue samples were snap-frozen 
immediately (~ 1 min) after removal and stored in -80°C.  
 
Patient treatment protocols 
All patients included in the studies received NAC. In paper I, the patients were treated 
with weekly doxorubicin (14mg/m2) for 16 weeks before surgery. In paper II, first line 
treatment with four doses of epirubicin (90 mg/m2) or paclitaxel (200 mg/m2) was 
administrated to the patients every third week. In case of insufficient response or the 
tumor was still inoperable after four doses, cross-over to second line treatment or 
extension of four doses of the same first line treatment was given. In paper III, only pre-
treatment breast cancer tissue samples were used. All patients underwent a mastectomy 
and post-operative radiation therapy. Patients with hormone receptor positive tumors 
(ER and/or PgR ≥ 10 fmol/mg protein [115] or ≥ 10% positive cells detected with 
immune histochemistry) were treated with tamoxifen for five years after surgery. 
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Clinical treatment response and breast cancer survival 
Clinical tumor response was evaluated by comparing caliper measurements pre- and 
post-treatment and assigned according to the WHO criteria (Table 1.2). Patients 
included in paper I and II had either a partial response or stable disease in response to 
NAC. Survival time was defined as the time interval from diagnosis until the end of the 
observation period (five years). Patients deceased within five years after diagnosis were 
classified as non-survivors whereas patients surviving five years or more were classified 
as survivors. Patients that died of other causes than breast cancer were censored.    
 
The cell lines  
All cell lines included in paper III were obtained from American Type Culture 
Collection (ATCC, www.atcc.org). Non-malignant MCF-12A and two malignant 
human mammary epithelial cell lines, MCF-7 and MDA-MB-231, were used in the cell 
experiments. MCF-7 is an estrogen-sensitive and weakly malignant, while MDA-MB-
231 is an estrogen-independent and highly malignant breast cancer cell line. The cells 
were grown in their respective media supplemented with fetal bovine serum (FBS), 
penicillin, and streptomycin as previously described [116]. All cells were cultured at 
37°C in 5% CO2 and were used while sub confluent (approximately ~70%).   
 
Tumor cell content 
In paper I, breast cancer tissue samples were first analyzed by 1H HR MAS MRS before 
formalin-fixed, embedded in paraffin, and stained with hematoxylin-eosin-saffron 
(HES). In paper II and III, imprint cytology smears were prepared from each tissue 
sample and stained with May-Grünwald-Giemsa prior to 1H HR MAS MRS. The tumor 
cell content was determined microscopically by a pathologist. For cells in culture (paper 
III), trypan blue staining was used as vital stain for cell counting. 
 
 
 
 
 
 
Figure 3.1: Microscopic images of breast cancer tissue samples and cultured cells. 
MCF-7Histology Imprint cytology MDA-MB-231
Breast cancer tissue samples Breast cancer cell lines
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3.3 1H HR MAS and 1H HR MRS experiments 
Sample preparation  
Patient tissue samples were blinded and randomized prior to 1H HR MAS MRS analysis 
(http://www.random.org/lists/). The samples were randomized based on chemotherapy 
agents (paper II), clinical treatment response, and pre- and post-treatment samples. Pair 
of samples (pre- and post-treatment) from each patient were analyzed in series to 
minimize experimental artifacts. Tumor tissue (15.5±3.0 mg) and phosphate buffered 
saline (PBS, 3 μl) in D2O containing 98.2 mM TSP for chemical shift referencing were 
added to a 30 μl leak-proof disposable insert (Bruker Biospin Corp, USA) and 
transferred to a MAS rotor. 1H HR MAS spectra were obtained using a Bruker AVANCE 
DRX600 spectrometer (Bruker Biospin GmbH, Germany). Samples were spun at 5 kHz 
at 4°C to minimize tissue degradation. Spin-echo spectra (cpmgpr; Bruker) were 
recorded for all the samples as previously described [39]. In addition, a single pulse 
experiment including the ERETIC signal (ereticpr.drx; Bruker) as a quantification 
reference [111] was performed for samples included in paper I and III.  
 
For cell cultures, the lipid and water-soluble metabolites were extracted using a dual-
phase extraction method based on methanol/chloroform/water as previously described 
[74]. The water-soluble and lipid fractions were dissolved in deuterated solvents 
containing 0.24x10-6 mol TSP and 2.17x10-7 mol tetramethylsilane (TMS) respectively, 
as quantification references and chemical shift standards. Fully relaxed 1H HR MRS 
spectra were obtained using a Bruker AVANCE 500 spectrometer (Bruker Biospin Corp).  
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MRS protocols 
The different MRS protocols for the recorded spectra are summarized in Table 3.2.  
 
Table 3.2 MRS protocols  
 Tissue samples Cultured cells 
Method 1H HR MAS MRS 1H HR MRS 
Spectrometer Bruker advanced 600 (14.1 T) 
Bruker advanced 500 
(11.7 T) 
Pulse program Spin-echo Single pulse with ERETIC reference Single pulse 
 cpmgpr; Bruker ereticpr.drx; Bruker zg; Bruker 
Parameters Paper I + II + III Paper I + III Paper III 
Flip angle 90° 60° 45° 
NS 128 128 128 
Time domain size 32K points 64K points 32K points 
AQ 1.64 s 3.28 s 0.819 s 
Sweep width 10 kHz/16.7 ppm 10 kHz/ 16.7 ppm 6 kHz/ 12.0 ppm 
TE 285 ms - - 
TR 3.93 s  18.28 s 12.70 s 
NS, number of scans; AQ, acquisition time; TE, total echo time; TR, repetition time. 
 
The different acquisition times (AQ) used in the spin-echo and ERETIC pulse programs 
are appropriate for breast tissues. The single pulse spectra with the ERETIC reference of 
tissue samples and single pulse spectra of cultured cells were acquired with short flip 
angles (60° and 45°, respectively) and long repetition times to avoid saturation of the 
signals. The pulse sequence was repeated (NS=128) to achieve a good signal-to-noise 
ratio (S/N). The spin-echo sequence was used to suppress signals with short T2 values 
(e.g. lipids and macro molecules). A total echo time (TE) of 285 ms was obtained by 
using a Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence with 1 ms echo delay and 
136 loops (Figure 3.2). Zero-filling was applied to increase the digital resolution (paper 
I-III, tissue samples). Spectra were Fourier transformed into 128 K after 0.3 Hz line 
broadening and chemical shifts were calibrated to the TSP signal at 0 ppm (paper I-III, 
tissue samples).  
 
 
 
 
Figure 3.2: Schematic illustration spin-echo sequence used in paper I-III. 
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3.4 Gene and protein experiments 
In paper III, total RNA isolation from human breast cancer tissue samples and cultured 
cells was performed using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s protocol. The concentration and purity of RNA yield were determined 
with a NanoDrop ND-1000 Spectrophotometer (Thermo Scientific). In addition, the 
integrity of RNA (RIN) of the tissue samples was measured using Bionalyzer 2100 
(Agilent). Total RNA (1 μg) was used for preparation of cDNA by SuperScript III First-
Strand Synthesis SuperMix (Invitrogen). The mRNA levels of GDPD1-5, CHKA, and 
PLD1 were measured by qRT-PCR using the iCycler real-time PCR detection system 
(Bio-Rad) and iQ SYBR Green Supermix (Quanta BioSciences). Gene specific primers 
(Invitrogen) were designed using the Primer-BLAST tool 
(http://www.ncbi.nlm.nih.gov). The relative fold change (R) in gene expression was 
calculated based on the threshold cycle (ct) using the ΔΔct method as R = 2−Δ(Δct) [117], 
where Δct = ct(target gene) − ct(housekeeping gene), and Δ(Δct) = Δct(experiment 
sample) − Δct(control sample).   
 
Protein isolation was carried out using lysis buffer containing a protease inhibitor 
cocktail (P8340, Sigma-Aldrich). GDPD5 Western blotting for the three tested cell lines 
was performed as previously described [116]. The proteins were denatured and 
separated by SDS-PAGE (sodium dodecyl sulfate–polyacrylamide gel electrophoresis). 
Thirty micrograms of total protein, as determined by a modified Lowry assay (Bio-
Rad), was loaded in each lane, and two lanes were loaded with molecular weight 
standard (BenchMark, Life Technologies). The proteins were transferred to a membrane 
and incubated for 1 hour with a dilution (1:500) of primary polyclonal anti-GDPD5 
antibody (Cat. No. AP10992c, Abgent Inc.) followed by incubation with horseradish 
peroxidase (HRP) conjugated secondary antibody (Amersham Life Science). 
Visualization was performed using the Supersignal West Pico chemiluminescent 
substrate kit (Pierce Biotechnology). The membrane was recorded on Blue Bio film 
(Denville Scientific). Quantitative densitometry of the GDPD5 proteins was performed 
using the Gel-analysis-tool in ImageJ (Wayne Rasband, NIH, Bethesda, MD). We did 
not have sufficient tumor material to run immunoblots on the patient samples.  
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3.5 Data analyses 
Tissue samples with low tumor cell count and poor spectral quality were excluded from 
further analyses.  
 
3.5.1 Multivariate data analyses 
The different preprocessing and validation methods of spin-echo spectra used for 
multivariate data analyses are presented in Table 3.3. Prior to spectral preprocessing, 
signals from water, large lipid residuals, and ethanol contamination were removed from 
the spectra. Data analyses were performed in Matlab R2009a (The Mathworks, Inc.) 
using PLS_Toolbox 6.2.1 (Eigenvector Research). 
 
Table 3.3 Multivariate data analyses of spin-echo spectra 
 Paper I  Paper II  
 PLS-DA/ GA PLS-DA Multi level PLS-DA/ 
Preprocessing methods  PLS-DA 
Average Reduced by a factor of 2 Reduced by a factor of 2 
Baseline correction Baseline offset Asymmetric least squares and baseline offset 
Normalization Equal total area Equal total area 
Peak alignment SpecAlign icoshift 
Mean centering yes yes 
Variable selection Genetic algorithm - 
Validation methods   
Validation Full cross-validation 10% random test set 
Permutation  - yes 
PLS-DA, partial least squares discriminant analysis; GA, genetic algorithm.  
 
Spectral data from each sample were reduced by a factor of 2 using the mean value of 
two consecutive data points. Baseline offset was corrected by shifting the minimum 
intensity value of each spectrum to zero. In paper II, asymmetric least squares baseline 
correction was used in addition to baseline offset [118]. The spectra were peak aligned 
using SpecAlign algorithm with the mean spectrum serving as reference (paper I) [96] 
and icoshift (paper II) [97]. Mean centering was performed by subtracting the average 
spectrum of all the spectra from each spectrum. GA variable selection prior to PLS-DA 
was performed in paper I.  
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In paper I, full cross-validation was used due to the low number of samples (n ≤ 26). In 
paper II, validation was performed with randomly chosen test set using 90% of the 
patients for training and the remaining 10% for testing. This procedure was repeated 20 
times and the average validated classification results were calculated. To avoid biased 
results, the same number of LVs was used for all repetitions and was chosen by cross-
validation of the whole data set. The VIP scores were used to assist the interpretation of 
the PLS-DA loadings. Permutation testing was performed by randomly assigning the 
class labels to the samples and the average results were calculated as described for the 
original data (90% training set, 10% test set, 20 repetitions). The permutation procedure 
was repeated 1000 times in which the class labels were reshuffled each time. The 
classification result of the original data was compared to the distribution of 
classification results from the permutation. P-values ≤ 0.05 were considered significant.  
 
3.5.2 Metabolite quantification 
The single pulse spectra with the ERETIC reference of tissue samples and single pulse 
spectra of cultured cells were used for metabolite quantification. Tissue metabolite 
quantification using curve fitting (PeakFit v 4.12, SeaSolve Software Inc.) and the 
ERETIC signal as reference was performed in paper I and III. The metabolite 
concentration was calculated using Equation I [111]. In paper III, metabolite 
quantification of cell extracts was determined by peak integration (MestReC 4.9.9.6 
software, Mestrelab Research) using Equation II [74]. The signal integrals of TSP and 
TMS were used as references for the water-soluble and lipid extracts, respectively. In 
paper II, relative metabolite intensities were calculated by integrating the peak areas of 
spectra normalized to equal total areas after removal of signals from water, lipid 
residuals, and ethanol contamination (Matlab R2009a, The Mathworks, Inc.).  
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AMET : metabolite area 
AERETIC: ERETIC area 
kMET : number of protons of the metabolite signal 
nERETIC: number of moles in the ERETIC signal  
msample: sample mass (gram)  
 
IMET : metabolite integral 
ITSP/TMS: TSP/TMS integral 
kMET : number of protons of the metabolite signal 
nTSP/TMS: number of moles in the TSP/TMS signal  
mcell: cell count 
mvolume: cell volume 
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Statistical analyses were performed using SPSS (SPSS 16.0 Inc.). The Kolmogorov-
Smirnov test was used to evaluate normality of the data. For normal distributed data, the 
statistical differences between multiple groups and paired samples were determined 
using two-tailed unpaired and paired T-test, respectively. For non-normal distributed 
data, the grouped Mann-Whitney and paired Wilcoxon Signed Ranks tests were used. P-
values of ≤ 0.05 were considered to present significant differences between groups. 
 
In paper I, receiver operating characteristic (ROC) curve analysis was performed using 
metabolite concentrations obtained from pre-treatment tumor tissue samples to define 
cut-off levels for prediction of treatment response and breast cancer survival. 
 
3.5.3 Gene and protein expressions 
The Grubbs (GraphPad Software) test was performed to detect significant statistical 
outliers for each gene set (GDPD1-5, CHKA, and PLD1) of the patient tumor samples 
(significant level alpha ≤ 0.05).  Maximally one outlier was discarded per set. The 
normality of the data was evaluated by the Kolmogorov-Smirnov test (SPSS 16.0 Inc.). 
The unpaired two-tailed T-test (SPSS 16.0 Inc.) was performed to detect significant 
differences between the tested groups. Pearson correlation (SPSS 16.0 Inc.) was 
calculated to investigate the linear correlations between GDPD1-5 gene expressions and 
choline phospholipid metabolites in human breast tumors and cell lines, but also to 
examine the correlations between GDPD5 versus CHKA and GDPD5 versus PLD1 
gene expressions. In human breast cancer cells, GDPD5 protein levels were also related 
to choline phospholipid metabolite and CHKA protein levels. P-values of ≤ 0.05 were 
considered to be significant. 
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4 Summary of papers 
 
Paper I 
Predicting long-term survival and treatment response in breast cancer 
patients receiving neoadjuvant chemotherapy by MR metabolic profiling 
 
This paper aimed to evaluate whether MR metabolic profiling can be used for prediction 
of long-term survival (≥ 5 years) and monitoring of treatment response in LABC 
patients receiving doxorubicin monotherapy. 
 
1H HR MAS MR spectra of pre- and post-treatment tissue samples from LABC patients 
(n=33) were acquired. Tissue metabolite concentrations of PC, GPC, Cho, glycine, and 
taurine were quantified using PeakFit and the ERETIC signal as reference. ROC curves 
analysis was performed to define their potential to predict patient survival and treatment 
response. The MR metabolite profiles were related to long-term survival and treatment 
response by PLS-DA and PLS-DA with GA variable selection.  
 
A significant decrease in GPC post-treatment was associated with long-term survival 
(p=0.046) and partial response (p=0.014) to NAC. Long-term survival was best 
predicted by GPC using ROC analysis (sensitivity 66.7%/specificity 62.5%), while 
taurine had the best predictive value of clinical treatment response (sensitivity 72.7%/ 
specificity 63.2%). GA PLS-DA multivariate classification models successfully 
discriminated between patients with long-term survival (≥ 5 years, survivors) and 
patients who died of breast cancer recurrence (< 5 years, non-survivors), resulting in 
82.7% and 90.2% CV classification accuracy, pre- and post-treatment, respectively. The 
pre-treatment MR metabolite profiles of survivors were characterized by higher levels 
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of tCho and lower levels of lactate compared to non-survivors. Classification of clinical 
treatment response using GA PLS-DA was not successful for this patient cohort.  
 
Our results demonstrate that 1H HR MAS MR metabolic characteristics of breast tumors 
could potentially assist the classification and prediction of long-term survival in LABC 
patients, in addition to being used for evaluation of treatment response to NAC. 
 
 
 
Paper II 
Prognostic value of metabolic response in breast cancer patients receiving 
neoadjuvant chemotherapy 
 
The aim of this paper was to examine the tumor metabolic changes in patients with 
LABC caused by NAC, and relate these changes to long-term survival (≥ 5 years) and 
clinical treatment response. 
 
LABC patients (n=89) participating in a randomized multicenter study were allocated to 
receive either NAC as epirubicin or paclitaxel monotherapy. Tumor tissue samples 
obtained pre- and post-treatment were analyzed by 1H HR MAS MRS. MR metabolite 
profiles were examined by PLS-DA and paired PLS-DA (or multilevel PLS-DA). The 
metabolites most important for the classification were identified by VIP scores and 
quantified by spectral integration of the metabolite peaks.  
 
All patients had a significant metabolic response to NAC, and the pre- and post-
treatment spectra could be discriminated with 68.9% and 87.9% CV classification 
accuracy by PLS-DA and multilevel PLS-DA, respectively (p<0.001). The metabolic 
responses appear to be similar for the two chemotherapeutic agents. Different metabolic 
responses to NAC were observed in patients with long-term survival (≥ 5 years, 
survivors) and patients who died of breast cancer recurrence (< 5 years, non-survivors). 
Survivors experienced a decrease in the levels of GPC (p<0.001), PC (p<0.001), Cho 
(p=0.013), glycine (p=0.047), and increase in glucose (p=0.002) levels in response to 
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NAC, while non-survivors had an increase lactate (p=0.004) levels in response to NAC. 
The metabolic responses to NAC were similar in the different clinical treatment 
responses.  
 
To conclude, the tumor metabolic response to NAC was related to breast cancer 
survival, but not to clinical treatment response. Monitoring metabolic responses to NAC 
by 1H HR MAS MRS may provide information related to individual prognosis. 
 
 
Paper III 
Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) 
expression correlates with malignant choline phospholipid metabolite 
profiles in human breast cancer 
 
Choline phospholipid metabolism is altered in cancer. The gene(s) encoding for the 
GPC-PDE(s) responsible for GPC degradation in breast cancers have not yet been 
identified. In this paper, we aimed to investigate the role of GDPDs in choline 
phospholipid metabolism in breast cancer. 
 
Two human breast cancer cell lines (n=8 and 10) and primary human breast tumor 
samples (n=19) were studied with combined MRS and qRT-PCR to investigate the 
potential role of GDPD1-5 as GPC-PDE encoding genes and to determine their 
relationship with CHKA and PLD1 in choline phospholipid metabolism.   
 
Out of five GDPDs tested, GDPD5 was found to be significantly overexpressed in 
highly malignant ER- compared to weakly malignant ER+ human breast cancer cells 
(p=0.027) and breast tumors from patients (p=0.015). GDPD5 showed significantly 
positive correlations with PC (p<0.001), total choline (tCho) (p=0.007) and PC/GPC 
(p<0.001) levels in human breast tumors. GDPD5 showed a trend towards negative 
correlation with GPC levels (p=0.130). Human breast cancers with malignant choline 
metabolite profiles consisting of low GPC and high PC levels highly co-expressed 
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GDPD5, CHKA, and PLD1, while cancers containing high GPC and relatively low PC 
levels displayed low co-expression of GDPD5, CHKA, and PLD1.  GDPD5, CHKA 
and PLD1 were significantly overexpressed in highly malignant ER- tumors in our 
patient cohort.   
 
Our study identified GDPD5 as a GPC-PDE that likely participates in regulating choline 
phospholipid metabolism in breast cancer, which possibly occurs in association with 
CHKA and PLD1. 
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5 Discussion 
 
The metabolic characterization of breast tumors by 1H HR MAS MRS may assist the 
prediction of long-term survival in LABC patients (paper I and II). The tumor metabolic 
responses to NAC were related to breast cancer survival, but not to clinically measured 
treatment response (paper II). High levels of lactate and glycine post-treatment were 
associated with poor outcome, while decreased choline phospholipid metabolite levels 
were observed in response to NAC in patients with long-term survival (paper I and II). 
Furthermore, GDPD5 was identified as a possible regulatory gene in choline 
phospholipid metabolism in breast cancer, and high co-expression of GDPD5, CHKA, 
and PLD1 were associated with increased malignancy (paper III). 
 
5.1 Patients and tumor samples 
The tumor samples obtained from open biopsies before NAC and during final surgery 
were collected from LABC patients from 1991 to 2003. All samples were immediately 
(~ 1 min) snap frozen after removal and stored in -80°C until used for 1H HR MAS 
MRS analysis in 2008 (paper I) and 2009 (paper II and III). No significant correlations 
have so far been found between storage time and tissue metabolite degradation 
determined by 1H HR MAS MRS [39, 119]. Furthermore, the tissue metabolite 
concentrations determined in our study are comparable to those previously reported for 
breast cancer tissue samples stored for five years or less [39, 111]. The integrity of RNA 
quantified by RIN-values was good (paper III). Altogether, this suggests that the storage 
procedure maintains the quality of the samples well, and potential gene and metabolite 
degradations should be minimal.  
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As 1H HR MAS MRS is a non-destructive method, tissue samples were further used for 
histological examinations to confirm the tumor cells content (paper I). In paper II and 
III, imprint cytology was used instead of histological sections to confirm the tumor cell 
content. Imprint cytology has been found to be a reliable, rapid, and easy 
complementary examination to histological sectioning [120]. Furthermore, the use of 
imprint cytology advantageously enabled the tissue samples to be further analyzed for 
gene and/or protein expressions after 1H HR MAS MRS (paper III).  
 
5.2 Metabolomics analyses 
Metabolomics analyses assess the downstream products of gene and protein 
expressions, and have shown to provide both predictive and prognostic information for 
several types of cancers [76, 77]. Multivariate and quantitative analyses of the 1H HR 
MAS MR spectra are of key importance for interpreting findings and validating the 
results. Therapeutic response is often not associated with the change in one biomarker, 
but rather with the combined influence of many molecular compounds. Multivariate 
statistical methods were used to identify patterns of several metabolites simultaneously 
and to discover metabolic features related to the discrimination between distinct classes. 
Absolute metabolite quantification has an added value, since the concentrations 
obtained can be compared to other studies and may be easier to interpret in a clinical 
setting. 
 
MR metabolite profiles of LABC tumors were related to treatment response and long-
term survival by PLS-DA and multilevel PLS-DA multivariate statistical methods. 
Proper validation of the PLS-DA models is necessary to avoid biased results. In paper I, 
validation of the multivariate models was performed by full cross-validation. This 
method is simple and widely used, but is also known to give large variance that may 
lead to overfitting of data and too optimistic results. However, full cross validation was 
a convenient choice for this smaller size data set when there were not enough samples 
for a separate test set. In paper II, validation was performed using randomly selected test 
sets and permutation testing. To avoid overfitted results, the number of LVs was 
optimized by cross-validation of the whole data set and the same number of LVs was 
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used for calculation in all repetitions. It is important to keep in mind that the result of 
classification models is largely dependent on the validation procedure and also the size 
of the data set, and that too optimistic results are usually due to inappropriate choice of 
validation [101].  
 
The study of the metabolic changes in tumors during NAC is important as it can assist 
in improving treatment of breast cancer patients focusing on personalized treatment 
strategies. Multilevel PLS-DA is a relatively new method for multivariate investigation 
of the paired structure within the different subjects [103] and was therefore used in 
paper II. This method enabled the detection of metabolic changes caused by NAC 
within each patient by subtracting the between patient variations from the data. 
Metabolic changes detected by multilevel PLS-DA were significantly better then 
unpaired PLS-DA, resulting in 87.9% versus 68.9% CV classification accuracy, 
respectively (paper II). Thus, taking advantage of the multilevel structure in the data set 
was clearly beneficial. 
 
Metabolites that were found to be important for the multivariate classification models 
were quantified (paper I and II). To quantify the metabolites in the 1H HR MAS MR 
spectra, the area of the peaks was determined by curve fitting (paper I and III). Spectral 
prior knowledge (multiplicity etc) is essential for the quality of the fit. Curve fitting is a 
proper method for area determination of multiple overlapping signals and is a more 
accurate and reliable method than peak integration. However, curve fitting by Peakfit 
can be time-consuming. Automatic model-based curve fitting, such as LCModel [121], 
has been used for quantification of 1H HR MAS spectra of brain tissue [122, 123]. 
LCModel facilitates the separation of overlapping signals by fitting the data to a linear 
combination of the complete spectra from pure metabolite solutions; so called basic sets 
[123]. Such basic sets have not been generated for 1H HR MAS MRS spectra of breast 
cancer. Curve fitting using PeakFit can be biased by subjective interpretations. Routines 
for curve fitting were standardized, and curve fitting was performed by one user (paper I 
and III). We thus consider the inter-spectral effects on peak area calculations to be 
small. In paper II, the relative metabolite intensities were found by integrating the peak 
areas in mean normalized spectra. This approach is useful in terms of confirming the 
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significant differences in the metabolite levels as observed in the loading plots from 
multivariate analyses. However, the intensity values are not transferable for comparison 
with results from other studies.  
 
The electronic external reference method ERETIC used in paper I and III is a promising 
alternative to the use of internal quantitative references [109-111]. There are no 
concerns about metabolic activity and visibility when using ERETIC. However, 
quantification using the ERETIC signal is more sensitive to RF field inhomogeneities of 
HR MAS probes [124] than chemical internal references such as TSP [111]. The effect 
of RF field inhomogeneities can be reduced by using an insert which ensure that the 
sample is within the most homogeneous range of the RF coil, thus minimizing signal 
loss (paper I-III). A higher relative error for ERETIC (8.4%) compared to TSP (2.7%) 
has been observed using 1H HR MAS MRS for quantification of creatine in a standard 
solution [111]. However, ERETIC is still considered as the best approach for 
quantifying tissue metabolites in 1H HR MAS MRS, as TSP can bind to proteins and 
other membrane components present in the sample causing an overestimation of 
metabolite concentrations. Periodical calibration of the ERETIC signal is necessary for 
ensuring accurate quantification over time [109, 110]. In this thesis, the samples were 
randomized and analyzed within a short period of time to reduce the effect of calibration 
and technical artifacts. Pulse length based concentration determination (PULCON) is 
another external reference technique that uses the principal of reciprocity to correct 
absolute intensities relative to an external standard spectrum [125, 126]. To our 
knowledge, no studies using PULCON for quantitative 1H HR MAS MRS have so far 
been published (Pubmed, Scopus). 
 
Metabolite quantification was related to tissue sample weight, as done in previous 
studies of 1H HR MAS MRS [39, 111, 127]. 1H HR MAS signals of tumor tissue 
samples arise from both cancer cells and tumor stroma. The spectra therefore represent 
the average signal from all the constituents in the sample. In general, this is also the case 
for other types of molecular profiling analyses, including transcriptomics and genomics.  
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5.3 MR metabolic profiling and clinical treatment response 
The most beneficial use of NAC for LABC patients is still under discussion, and both 
combinations of different chemotherapies, but also monotherapy, have been suggested  
[10, 128, 129]. Studies investigating chemoresistance to monotherapy as well as the 
combination of chemotherapies can help optimize and improve the treatment of breast 
cancer. The clinical response is also of interest as a surrogate marker for survival. 
Several studies have shown that pathological complete response (pCR) to NAC, which 
is obtained in 3-26% of breast cancer patients is associated with improved recurrence-
free and overall survival [10, 21]. Thus, an improved understanding of breast tumor 
molecular characteristics would be essential in the design of personalized cancer 
therapy, thereby achieving better prognosis. 
  
In this thesis, no valid multivariate classification models for the prediction of clinical 
response could be generated using pre- or post-treatment spectra (paper I and II). In 
paper I, metabolic changes in response to NAC were evaluated by comparing quantified 
individual metabolites obtained pre- and post-treatment, because multilevel PLS-DA 
was yet not implemented as one of our multivariate analytical tools. In patients with 
partial response, only GPC was found to be significantly decreased, and a decrease in 
tCho approached significance. In paper II, all patients experienced significant metabolic 
changes in response to NAC analyzed by multilevel PLS-DA. However, similar 
metabolic responses were observed in both patients with partial response and with stable 
disease. In both groups, treatment led to increased levels of lactate and glycine and 
decreased levels of GPC, while the levels of PC were markedly decreased for some 
patients. These metabolic changes were similar to those observed for the entire patient 
cohort.  
 
The tCho level detected with in vivo MRS has been suggested as a biomarker for 
diagnosis and treatment evaluation of breast cancer [57, 58]. Several studies have found 
decreased tCho levels in response to NAC to be associated with better clinical response 
[60, 62, 130-132]. Docetaxel treatment of MCF-7 breast cancer xenografts also resulted 
in decreased in vivo tCho levels and cell density [133]. In another study, ex vivo PC 
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levels were found to decrease after treatment with docetaxel in MCF-7 breast cancer 
xenograft models [134]. Significantly decreased GPC levels in patients with partial 
response may suggest a better response to NAC (paper I). Unfortunately, GPC cannot 
be distinguished from the other choline metabolites by in vivo MRS due to low spectral 
resolution.  
 
The lack of patients with progressive disease and complete response in our analyzed 
cohort could help explain why no clear metabolic differences in response to NAC 
between the two response groups were observed (paper I and II). According to the 
protocol, treatment should be interrupted if/when the patients experienced progressive 
disease. For patients with complete response, no tumor tissue is left for a post-treatment 
sample. For these patients, examination of metabolic changes in response to NAC of 
tissue samples taken at an earlier time point then at final surgery would be of interest. 
Inclusion of pre-treatment samples of patients with progressive disease and complete 
response could contribute to reveal clearer differences in metabolite profiles between 
the clinical response groups that can be used to assist the prediction of clinical response.  
 
The finding that all patients had a similar metabolic response to NAC could be due to 
the fact that only two patients had an equal or increased tumor size after NAC (paper 
II). Thus, nearly all patients thus had a reduction in tumor size, although the tumor 
reduction was small for patients with stable disease. In this thesis, treatment response 
was defined according to the WHO criteria (Table 1.2), which define stable disease as < 
50% reduction to < 25% increase in tumor volume. We can postulate that different 
response criteria for stable disease (lower threshold for reduction in tumor volume) can 
affect the findings in paper I and II. The differences in response criteria have shown to 
influence the prediction of response to NAC by in vivo MRI [135].    
 
The fact that all patients had a significant metabolic response to NAC could suggest a 
difference in metabolite profiles due to differences in sampling procedures for the two 
time points. However, the tumor samples obtained before NAC were excised during 
open biopsy surgery, which should be quite comparable to the sampling procedure at 
final surgery. Moreover, all samples were snap-frozen and stored in the same way. 
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Thus, we consider the differences in sampling procedures at pre and post-treatment to 
have small effects on the metabolite profiles. 
 
The metabolic response to NAC is also dependent on the molecular effects of the given 
chemotherapeutic agents. Anthracyclines, such as doxorubicin and epirubicin, are 
capable of inducing DNA strand breakage and apoptosis [23-25], while paclitaxel 
causes mitotic arrest by disturbing the breaking and rearranging of microtubules in the 
cells [26]. However, the main function of all these drugs is to cause disturbance of the 
cell cycle and cell death. The metabolic responses to epirubicin and paclitaxel could not 
be distinguished, which suggests that they have the similar effects on tumor cell 
metabolism (paper II). 
 
5.4 MR metabolic profiling and long-term survival 
The definition of long-term survival is not unified in the literature. A long-term survivor 
is defined by the American Cancer Society as a person who is still alive 5 years after 
diagnosis [136]. LABC consist of a heterogeneous group of patients with variable 
prognosis and with a lower 5-year survival rate than early stage breast cancer [10]. We 
thus consider the use of the term long-term survival to be appropriate for our studies.  
 
Altered cell metabolism is suggested as a new emerging hallmark of cancer [34]. MR 
detected metabolite profiles have been found to assist the diagnosis and treatment 
monitoring of breast cancer [89, 90], and have also been found to correlate to 
parameters of clinical importance such as tumor grade, axillary lymphatic spread, and 
hormone receptor status [39, 91, 92]. LABC patients constitute a heterogeneous group 
with variable prognosis, and it is therefore a challenge to identify valid prognostic 
factors for this patient group. In addition, prediction of survival in LABC patients 
receiving NAC is difficult as the treatment will affect the prognostic value of tumor 
size, grade and lymph node status.  
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Several studies have shown that a pathological complete response to NAC is associated 
with improved breast cancer survival [21, 22]. However, approximately 80% of patients 
will have residual tumor in the breast after NAC [22]. Thus, molecular characterization 
with identification of new prognostic factors and therapeutic targets for breast cancer 
would greatly benefit the assessment of prognosis.  
 
In this thesis, the potential of MR metabolomics to predict long-term breast cancer 
survival was investigated. A summary of the main findings is presented in table 5.1. In 
paper I, metabolic changes in response to NAC were detected by quantification of 
individual metabolites. Lactate could not be quantified using the present 1H HR MAS 
MRS protocol due to heavily overlapping signals from lipids. In paper II, different 
metabolic responses to NAC were observed in survivors and non-survivors by 
multilevel PLS-DA.  
 
Prediction of long-term survival was investigated using 1H HR MAS spectra of pre- and 
post-treatment tumor samples by PLS-DA and metabolite quantification. In paper I, 
long-term survival could be predicted using pre- and post-treatment spectra. Better 
classification was obtained post-treatment. In paper II, long-term survival could only be 
predicted from the post-treatment spectra. These results suggest that the difference 
between survivors and non-survivors post-treatment is mainly caused by metabolic 
response to NAC. Thus, the metabolite profiles of post-treatment samples may be a 
better and more accurate indicator of patient prognosis than pre-treatment samples. 
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Table 5.1 Summary of metabolite profiles pre- and post-treatment and metabolic 
changes observed by multivariate analysis and quantification related to long-term 
survival in paper I and II.  
  Paper I Paper II 
  Multivariate Quantification Multivariate Quantification 
M
et
ab
ol
ite
 
pr
of
ile
s 
 
Pre-treatment 
non-survivors 
vs survivors* 
× Lac 
   
 ØtCho 
No significant 
values 
No significant 
model NA 
 
M
et
ab
ol
ic
 c
ha
ng
es
 
in
 re
sp
on
se
 to
 
tre
at
m
en
t 
Survivors NA ØGPC and Cho 
ØGPC 
 
Ø Gly, GPC 
PC, and Cho  
Non-survivors NA No significant values × Lac × Lac 
M
et
ab
ol
ite
 
pr
of
ile
s 
 
 
Post-treatment 
non-survivors 
vs survivors* 
× Lac, Gly, 
and tCho 
No significant 
values 
× Lac, Gly 
 
× Gly 
 
NA, not applicable. *the results describe the metabolite profiles of non-survivors compared to 
survivors. Metabolite quantification was performed for Lac (not in paper I), Gly, GPC, PC, Cho, 
and Tau. 
 
In paper I, higher levels of lactate were observed pre- and post-treatment in non-
survivors compared to survivors. In paper II, non-survivors had a significant increase in 
lactate levels resulted in higher lactate levels in non-survivors compared to survivors at 
post-treatment (paper II). High lactate levels have been found to correlate with 
increased risk of radiation resistance, high incident of distant metastases and recurrence, 
and low survival rates in several types of cancers [42-44]. However, molecular 
mechanisms behind the role of lactate on malignant behavior of cancer cells are not 
fully understood. Recently, modification of cell energy metabolism has been suggested 
as an emerging hallmark of cancer [34]. Cancer cells can reprogram their energy 
metabolism to convert most glucose to lactate regardless of the oxygen supply, a 
phenomenon known as aerobic glycolysis (the Warburg effect). Aerobic glycolysis is 
possibly an adaption to intermittent hypoxia; protecting cancer cells from acid-induced 
toxicity, and facilitating the uptake and incorporation of nutrients needed for cell 
proliferation [36, 37]. In return, HiF-1 hypoxia induced gene can accentuate glycolysis 
by activation of multiple enzymes involved in the glycolytic pathway, including LDH, 
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the enzyme responsible for conversion of pyruvate to lactate [46-49, 51, 52]. Lactate 
may therefore serve as a maker for both aerobic glycolysis and hypoxic responses in 
tumors. Increased aerobic glycolysis and tumor hypoxic responses have been shown to 
facilitate cell proliferation, resistance to apoptosis, angiogenesis, and increased risk of 
metastasis in cancers [37, 38, 50]. Inhibition of LDH has shown to reduce the glycolytic 
activity associated with a decrease in tumor proliferation of breast cancer animal models 
[137]. In breast cancer, HiF-1 expression is highly associated with tumor progression, 
metastasis, therapy resistance and mortality [138, 139]. Anthracyclines have been 
shown to inhibit the transcriptional activity of HiF-1 by blocking its binding to DNA 
[140]. Thus, increased lactate levels observed in non-survivors in response to NAC may 
also be a marker for chemotherapy resistance in these patients. It has also been 
suggested that the resulting low pH mediated by high lactate levels may enhance the 
invasiveness of tumor cells and help them evade tumor-attacking immune cells [141]. 
This thesis suggests that the increased levels of lactate in response to NAC and higher 
lactate levels post-treatment observed in non-survivors may reflect enhancement of 
aerobic glycolytic activity and/or tumor hypoxic responses related to higher tumor 
malignancy and poor prognosis. Coherently, the glucose levels were increased in 
survivors but not in non-survivors in response to NAC (paper II). Increased glucose may 
be indicative of decreased aerobic glycolysis and tumor hypoxic response favorable of 
long-term breast cancer survival.  
 
In response to NAC, survivors had a significant decrease in glycine levels (paper II). 
This was reflected in the post-treatment spectra, showing significantly higher levels of 
glycine in non-survivors compared to survivors. The role of glycine in tumor 
malignancy is still unclear. Glycine is a downstream product of 3-phosphoglycerate, an 
intermediate of the glycolysis, but it can also be synthesized from Cho through the 
glycine-betaine pathway. The biomarker potential of glycine has been studied in human 
brain tumors, where it was found to positively correlate with tumor grade [40, 41]. 
Higher levels of glycine have been detected in the more aggressive basal-like breast 
cancer animal model compared to the luminal-like model [142]. This thesis suggests 
that the decreased glycine levels detected in survivors in response to NAC can possibly 
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be caused by altered glycolysis and/or reduced Cho levels associated with reduced 
tumor malignancy.  
 
In paper I, higher levels of tCho were observed in survivors compared to non-survivors 
before NAC. In response to NAC, survivors experienced a significant decrease in GPC 
and Cho measured by quantification. After NAC, lower levels of tCho were observed in 
survivors compared to non-survivors in the loading plot. However, the differences in 
tCho levels determined by quantification were not significant, probably due to high 
interpatient variation. In paper II, survivors experienced a significant decrease in GPC, 
PC, and Cho levels in response to NAC. The loading plot shows decreased GPC levels 
in survivors, while the levels of PC were markedly decreased for some patients. Overall, 
choline metabolite levels decreased in response to treatment in survivors, and appear to 
be higher in non-survivors compare to survivors post-treatment.  
 
The choline phospholipid metabolism is associated with proliferation, oncogenic 
signaling, and also tumor hypoxic responses [57].  PC and tCho levels have been shown 
to increase with increased malignancy in breast cancer cells [66]. CHKA, the enzyme 
that regulates the phosphorylation of Cho to PC, is known to play an important role in 
malignant transformation in several types of cancers [143]. Moreover, tCho levels have 
been shown to correlate with tumor grade and pharmacokinetic parameters of breast 
tumors, indicating a relation between choline phospholipid metabolism and tumor 
malignancy, but also angiogenesis [144, 145]. Hypoxic tumor regions co-localize with 
regions of high tCho, possibly occurring through the up-regulation of CHKA by HiF-1α 
[65]. This thesis demonstrates that LABC patients with decreased choline phospholipid 
metabolite levels, in particular GPC levels, in response to NAC have a better survival 
rate. Furthermore, MR metabolite profiles showing low levels of tCho, lactate, and 
glycine post-treatment could potentially be predictive of long-term survival. In a recent 
study, no differences in tumor tCho levels were found between early breast cancer 
patients with good and poor prognosis [111]. However, the assessment of prognosis in 
that study was based on the TNM classification system and not survival time.  
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Five subtypes of breast tumors characterized by gene expression pattern have been 
identified [146, 147]. A recent study shows the potential of combining transcriptomics 
and MR metabolic data for a more refine sub-classification of human breast cancers 
[148]. It is possible that the combined gene expression and MR metabolomics profiles 
will improve the molecular characteristics of breast cancer and help identify biomarkers, 
or combination of biomarkers, which in turn can assist treatment stratification and the 
prediction of patient outcome. 
 
5.5 GDPD5 in the regulation of choline phospholipid metabolism 
Both PC and GPC are known to be altered in cancer. In ovarian cancer, relatively low 
GPC compared to PC is typically observed [149]. In brain tumor, GPC levels is the 
dominant choline component in low compared to high grade gliomas [122]. Elevated 
GPC levels have been detected in lung [150] and prostate [151] cancer tissues compared 
to non-involved tissues. In normal mammary cell cultures, the GPC levels are relatively 
higher than the PC levels. During malignant transformation PC increases while GPC 
decreases, resulting in a switch from low to high PC/GPC ratio in cell cultures [66]. In a 
recent study, higher concentrations of GPC have been observed in basal like (poor 
prognosis) compared to luminal like (good prognosis) breast cancer xenograft 
models[142]. While recent research studies have focused on the molecular causes 
leading to elevated PC levels in cancer, relatively little effort has been made to elucidate 
the molecular causes behind the changes in GPC levels in cancers. The gene or genes 
responsible for the changes in GPC levels detected in breast cancer is still unknown.  
 
It is important to understand the molecular causes of the GPC levels detected in breast 
cancer because it is a part of the in vivo tCho signal that is increasingly being used in 
diagnosis and treatment monitoring of breast cancer patients [58-62].  As shown in 
paper I and II, targeting the enzymes involved in the regulation of GPC levels in breast 
cancers may be a good therapeutic target for anti-cancer treatment as significant 
decreased GPC in response to NAC was observed in patients with long-term survival 
and better clinical response.  
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In paper III, the role of GDPD1-5 in the regulation of choline phospholipid metabolism 
of human breast cancer was studied with combined MRS, gene and protein expressions. 
Out of five GDPDs tested, GDPD5 was found to be significantly overexpressed in 
highly malignant ER- compared to weakly malignant ER+ human breast cancer cells and 
breast tumor samples. GDPD5 showed significantly positive correlations with PC, tCho, 
and PC/GPC levels in human breast tumors, and a trend towards negative correlation 
with GPC levels. Human breast cancers with choline metabolite profiles consisting of 
high PC and low GPC levels highly co-expressed GDPD5, CHKA and PLD1, while 
cancers containing high GPC and relatively low PC levels displayed low co-expression 
of GDPD5, CHKA, and PLD1. High correlations were found between gene and protein 
levels of GDPD5 and CHKA. 
 
GDPD5 is a ubiquitously expressed transmembrane protein in human tissues, but has a 
relatively low expression in kidney and prostate tissues [152]. It has been suggested as a 
candidate gene for GPC-PDE as down-regulation of GDPD5 efficiently increased GPC 
levels, while overexpression of GDPD5 contributes to GPC reduction in mouse renal 
cells [75].  As a candidate gene for GPC-PDE, the GDPD5 expression is expected to 
inversely correlate with the GPC level. However, the expression of GDPD5 showed 
only a modest inverse correlation with GPC levels in breast tumors and cells (paper III). 
This observation suggests the possibility of additional genes responsible for the altered 
GPC level observed in breast cancer. Nucleotide pyrophosphatases/phosphodiesterases 
6 (NPP6) preferably hydrolyze choline-containing phospholipids or phosphodiesters, 
including GPC [153]. To date, the role of NPP6 is still unknown. The GPC level is also 
regulated by the gene expression of PLA2 and LYSO-PLA1 [74]. The correlations 
between these genes and GDPD5 have not been studied. 
 
The strong positive correlations between the expression of GDPD5 and PC, tCho, and 
PC/GPC levels are probable due to the co-expression of GDPD5, CHKA, and PLD1 
observed in breast tumors (paper III). CHKA plays an important role in oncogenic 
transformation and carcinogenesis in cancers [68, 143, 154, 155]. PLD activity, which 
degrades PtdCho to Cho, also plays a significant role in oncogenic transformation [156]. 
Overexpression of CHKA and elevated PC and tCho levels of breast cancer cells have 
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been associated with increases invasiveness and drug resistance [157]. Treatment with 
the CHK inhibitor Mn58b has shown to reduce PC levels and inhibit proliferation of 
cancer cells, and Mn58b therefore appears to have a potential as an anticancer drug 
[158]. The strong positive correlations between GDPD5, CHKA and PLD1 observed 
suggest the expression of GDPD5 to be associated with malignancy. Targeting GDPD5 
will most likely increase GPC levels. However, accumulation of GPC mediated by 
GDPD5 may disturb the recycle of Cho essential for renewed synthesis of PtdCho in the 
cell membrane. More studies are needed to investigate the mechanism and effects of 
GDPD5 for use as target in cancer treatment. 
 
Overexpression of GDPD5, CHKA, and PLD1 were found in ER- tumors compared to 
ER+ tumors (paper III). ER status is an important factor for the prediction of prognosis 
and is routinely used for treatment planning in the clinic. Consistent with our results, 
overexpression of CHKA has been associated with ER- breast tumors in a previous 
study [68]. However, ER- human breast cancer tumors have been related with higher 
levels of GPC and lower levels of PC compared to ER+ tumors [92]. The patients 
included in paper III have been stratified to match the ER status and choline metabolite 
profiles of the two breast cancer cell lines, MCF-7 and MDB-MB-231, thus a larger 
cohort is needed to elucidate the relationship between GDPD5 and ER status. This 
thesis identified GDPD5 as a GPC-PDE gene that likely participates in regulating 
choline phospholipid metabolism in breast cancer, which possibly occurs in cooperation 
with CHKA and PLD1. 
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6 Conclusions and future perspectives  
 
In this thesis, MR metabolic profiling of tumor tissue obtained from LABC patients was 
used to predict long-term survival and clinical treatment response to NAC by 
multivariate data analyses and metabolite quantification. Furthermore, the role of 
GDPDs in choline phospholipid metabolism was investigated.  
 
1H HR MAS MRS analysis of both pre- and post-treatment tumor tissue samples can be 
valuable as it provides information on metabolic changes in tumors during NAC. This 
thesis shows that epirubicin and paclitaxel had similar effects on tumor cell metabolism.  
It would be of interest to examine the metabolic responses in patients receiving other 
types of single drugs or multidrug treatment to improve the understanding of treatment 
effects on tumor metabolism. 
 
No clear differences in metabolic responses were detected between patients with partial 
response and stable disease, thus the prediction of clinical treatment response by MR 
metabolomics was not successful. However, it is possible that a cohort including also 
patients with progressive disease would reveal clearer differences in metabolite profiles 
between the clinical response groups. Also, the chosen response criteria might have 
contributed to the unsuccessful prediction of clinical treatment response from metabolite 
profiles. Different response criteria should be tested, in particular pathological measured 
response. Molecular characterization of tumors may help stratifying patients for 
individualized treatment, thereby achieving better prognosis. 
 
MR metabolite profiles of LABC patients contain prognostic information that is 
associated with survival status. In response to NAC, lactate is increased in non-
survivors, while survivors experience a decrease in glycine and choline phospholipid 
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metabolites. These metabolic changes are associated with tumor proliferation, glycolytic 
activity and hypoxia related to tumor malignancy and prognosis. Metabolite profiles 
consisting of higher levels of lactate, glycine, and tCho observed in non-survivors post-
treatment were shown to be predictive of low breast cancer survival rates. Monitoring 
metabolic responses to NAC by 1H HR MAS MRS may have the potential to assist the 
prediction of breast cancer survival and help identify new targets for therapeutic 
treatment.  
 
The relative fold change in gene expression of GDPD5 was correlated with choline 
phospholipid metabolite levels and with CHKA and PLD1 expressions. Future studies 
examining the effect of silencing GDPD5 alone or in combination with CHKA and/or 
PLD1 in breast cancer cells and xenograft models may provide new information about 
the potential of GDPD5 as anticancer targets of breast cancer. Studies investigating the 
correlation between GDPD5 and NPP6, PLA2, and LYSO-PLA1 in choline 
phospholipid metabolism would be of interest. Overexpression of GDPD5, CHKA, and 
PLD1 were found in ER- tumors compared to ER+ tumors. ER status is associated with 
treatment response and survival. However, a larger cohort is needed to investigate the 
correlation between GDPD5 and ER status.  
 
Findings from this thesis show that MR metabolomics can assist the identification of 
patients at high risk of breast cancer death, and help identify pathways for novel 
targeted treatment.  
 
 
 
 
References 
55 
 
References 
1. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast 
and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 
2011;378(9801):1461-84. 
2. Larsen IK, Grimsrud TK, Haldorsen T, Johannesen TB, Johansen A, Langseth H, et al. Cancer in 
Norway 2009 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer 
Registry of Norway, 2011 June. 
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A 
Cancer Journal for Clinicians. 2011;61(2):69-90. 
4. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and 
penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast 
Cancer Linkage Consortium. American journal of human genetics. 1998;62(3):676-89. 
5. Liu C, Zhang H, Shuang C, Lu Y, Jin F, Xu H, et al. Alterations of ER, PR, HER-2/neu, and P53 
protein expression in ductal breast carcinomas and clinical implications. Med Oncol. 
2010;27(3):747-52. 
6. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk 
factors, and genetics. BMJ. 2000;321(7261):624-8. 
7. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001;2(3):133-
40. 
8. Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and 
ductal breast carcinoma. JAMA : the journal of the American Medical Association. 
2003;289(11):1421-4. 
9. Tejler G, Norberg B, Dufmats M, Nordenskjöld B. Survival after treatment for breast cancer in a 
geographically defined population. Brit J Surg. 2004;91(10):1307-12. 
10. Mathew J, Asgeirsson KS, Cheung KL, Chan S, Dahda A, Robertson JF. Neoadjuvant 
chemotherapy for locally advanced breast cancer: a review of the literature and future directions. 
Eur J Surg Oncol. 2009;35(2):113-22. 
11. Franceschini G, Terribile D, Magno S, Fabbri C, D'Alba PF, Chiesa F, et al. Update in the 
treatment of locally advanced breast cancer: a multidisciplinary approach. Eur Rev Med 
Pharmacol Sci. 2007;11(5):283-9. 
12. AJCC Cancer Staging Manual, 7th edition. American Joint Committee on Cancer, 2009. 
13. Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J 
Clin Oncol. 2008;26(5):786-90. 
14. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of 
prognostic factors for long-term survivors of breast cancer. Breast Cancer Res and Treat. 
2008;107(3):309-30. 
15. Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, Dupont WD, et al. Estrogen receptor gene 
analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer 
Inst. 1995;87(6):446-51. 
16. Liu S, Chia SK, Mehl E, Leung S, Rajput A, Cheang MC, et al. Progesterone receptor is a 
significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in 
breast cancer patients. Breast Cancer Res and Treat. 2010;119(1):53-61. 
17. Zahnow CA. ErbB receptors and their ligands in the breast. Expert Rev Mol Med. 2006;8(23):1-
21. 
18. Chang JC. HER2 inhibition: from discovery to clinical practice. Clin Cancer Res. 2007;13(1):1-
3. 
19. Oakman C, Tenori L, Biganzoli L, Santarpia L, Cappadona S, Luchinat C, et al. Uncovering the 
metabolomic fingerprint of breast cancer. Int J Biochem Cell B. 2011;43(7):1010-20. 
20. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-
radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother 
Pharmacol. 1978;1(1):53-9. 
21. Jones RL, Lakhani SR, Ring AE, Ashley S, Walsh G, Smith IE. Pathological complete response 
and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer. 
2006;94(3):358-62. 
 
 
References 
56 
 
22. Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving 
pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis 
for breast cancer patients. Eur J Cancer. 2011;In Press. 
23. Kiyomiya K, Matsuo S, Kurebe M. Mechanism of specific nuclear transport of adriamycin: the 
mode of nuclear translocation of adriamycin-proteasome complex. Cancer Res. 
2001;61(6):2467-71. 
24. Marco A, Arcamone F. DNA complexing antibiotics: daunomycin, adriamycin and their 
derivatives. Arzneimittelforschung. 1975;25(3):368-74. 
25. Perego P, Corna E, De Cesare M, Gatti L, Polizzi D, Pratesi G, et al. Role of apoptosis and 
apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med 
Chem. 2001;8(1):31-7. 
26. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant 
breast cancer. Biochim Biophys Acta - Reviews on Cancer. 2008;1785(2):96-132. 
27. Gebski V, Lagleva M, Keech A, Simes J, Langlands AO. Survival effects of postmastectomy 
adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. J Natl 
Cancer Inst. 2006;98(1):26-38. 
28. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339(22):1609-18. 
29. Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R, et al. Long-term 
benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 
50 years of age with early breast cancer. J Clin Oncol. 2011;29(13):1657-63. 
30. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 
1981;47(1):207-14. 
31. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response 
evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 
2009;45(2):228-47. 
32. Mann RM, Kuhl CK, Kinkel K, Boetes C. Breast MRI: guidelines from the European Society of 
Breast Imaging. European radiology. 2008;18(7):1307-18. 
33. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell. 2000;100(1):57-70. 
34. Hanahan D, Weinberg Robert A. Hallmarks of Cancer: The Next Generation. Cell. 
2011;144(5):646-74. 
35. Warburg O. On the origin of cancer cells. Science (New York, NY). 1956;123(3191):309-14. 
36. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 
2004;4(11):891-9. 
37. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the 
metabolic requirements of cell proliferation. Science (New York, NY). 2009;324(5930):1029-33. 
38. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell 
proliferation. Annu Rev Cell Dev Biol. 2011;27:441-64. 
39. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR 
MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 
2006;19(1):30-40. 
40. Davies NP, Wilson M, Natarajan K, Sun Y, MacPherson L, Brundler MA, et al. Non-invasive 
detection of glycine as a biomarker of malignancy in childhood brain tumours using in-vivo 1H 
MRS at 1.5 tesla confirmed by ex-vivo high-resolution magic-angle spinning NMR. NMR 
Biomed. 2010;23(1):80-7. 
41. Righi V, Andronesi OC, Mintzopoulos D, Black PM, Tzika AA. High-resolution magic angle 
spinning magnetic resonance spectroscopy detects glycine as a biomarker in brain tumors. Int J 
Oncol. 2010;36(2):301-6. 
42. Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, et al. Elevated 
tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. 
Int J of Radiat Oncol. 2001;51(2):349-53. 
43. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, et al. High lactate 
levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in 
human cervical cancers. Cancer Res. 2000;60(4):916-21. 
44. Quennet V, Yaromina A, Zips D, Rosner A, Walenta S, Baumann M, et al. Tumor lactate 
content predicts for response to fractionated irradiation of human squamous cell carcinomas in 
nude mice. Radiother Oncol. 2006;81(2):130-5. 
 
 
References 
57 
 
45. Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, et al. Evaluation of 
lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy 
of biopsy tissues. Magn Reson Med. 2008;60(3):510-6. 
46. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. 
Oncogene. 2010;29(5):625-34. 
47. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. 
Genes Dev. 2009;23(5):537-48. 
48. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic 
reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11-20. 
49. Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and 
angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy. 
2007;53(4):233-56. 
50. Brown N, Bicknell R. Hypoxia and oxidative stress in breast cancer: Oxidative stress - its effects 
on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 
2001;3(5):323 - 7. 
51. Mathupala S, Colen C, Parajuli P, Sloan A. Lactate and malignant tumors: A therapeutic target at 
the end stage of glycolysis. J Bioenerg Biomembr. 2007;39(1):73-7. 
52. Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell Death Diff. 2008;15(4):621-7. 
53. Cuadrado A, Carnero A, Dolfi F, Jimenez B, Lacal JC. Phosphorylcholine: a novel second 
messenger essential for mitogenic activity of growth factors. Oncogene. 1993;8(11):2959-68. 
54. Yoon SJ, Lyoo IK, Kim HJ, Kim T-S, Sung YH, Kim N, et al. Neurochemical Alterations in 
Methamphetamine-Dependent Patients Treated with Cytidine-5[prime]-Diphosphate Choline: A 
Longitudinal Proton Magnetic Resonance Spectroscopy Study. Neuropsychopharmacol. 
2010;35(5):1165-73. 
55. Nakanishi T, Burg MB. Osmoregulation of glycerophosphorylcholine content of mammalian 
renal cells. Am J Physiol. 1989;257(4 Pt 1):C795-801. 
56. Zeisel SH. Choline: critical role during fetal development and dietary requirements in adults. 
Annu Rev Nutr. 2006;26:229-50. 
57. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev 
Cancer. 2011. 
58. Glunde K, Jacobs MA, Bhujwalla ZM. Choline metabolism in cancer: implications for diagnosis 
and therapy. Expert review of molecular diagnostics. 2006;6(6):821-9. 
59. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance 
spectroscopy in characterizing breast lesions. J Natl Cancer Inst. 2002;94(16):1197-203. 
60. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, et al. Neoadjuvant 
chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR 
spectroscopy--a pilot study at 4 T. Radiology. 2004;233(2):424-31. 
61. Manton DJ, Chaturvedi A, Hubbard A, Lind MJ, Lowry M, Maraveyas A, et al. Neoadjuvant 
chemotherapy in breast cancer: early response prediction with quantitative MR imaging and 
spectroscopy. Br J Cancer. 2006;94(3):427-35. 
62. Baek HM, Chen JH, Nalcioglu O, Su MY. Proton MR spectroscopy for monitoring early 
treatment response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol. 
2008;19(5):1022-4. 
63. Besterman JM, Duronio V, Cuatrecasas P. Rapid formation of diacylglycerol from 
phosphatidylcholine: a pathway for generation of a second messenger. Proc Natl Acad Sci. 
1986;83(18):6785-9. 
64. Bogin L, Papa MZ, Polak-Charcon S, Degani H. TNF-induced modulations of phospholipid 
metabolism in human breast cancer cells. Biochim Biophys Acta. 1998;1392(2-3):217-32. 
65. Glunde K, Shah T, Winnard PT, Jr., Raman V, Takagi T, Vesuna F, et al. Hypoxia regulates 
choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human 
prostate cancer model. Cancer Res. 2008;68(1):172-80. 
66. Aboagye EO, Bhujwalla ZM. Malignant Transformation Alters Membrane Choline Phospholipid 
Metabolism of Human Mammary Epithelial Cells. Cancer Res. 1999;59(1):80-4. 
67. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in 
phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer. 
2001;84(5):691-6. 
 
 
References 
58 
 
68. Ramirez de Molina A, Gutierrez R, Ramos MA, Silva JM, Silva J, Bonilla F, et al. Increased 
choline kinase activity in human breast carcinomas: clinical evidence for a potential novel 
antitumor strategy. Oncogene. 2002;21(27):4317-22. 
69. Hernandez-Alcoceba R, Fernandez F, Lacal JC. In vivo antitumor activity of choline kinase 
inhibitors: a novel target for anticancer drug discovery. Cancer Res. 1999;59(13):3112-8. 
70. Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Ramos MA, del Carmen Nunez M, 
Campos J, et al. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-
transformed cells. Oncogene. 2003;22(55):8803-12. 
71. Glunde K, Raman V, Mori N, Bhujwalla ZM. RNA interference-mediated choline kinase 
suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res. 
2005;65(23):11034-43. 
72. Krishnamachary B, Glunde K, Wildes F, Mori N, Takagi T, Raman V, et al. Noninvasive 
detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. 
Cancer Res. 2009;69(8):3464-71. 
73. Momchilova A, Markovska T, Pankov R. Ha-ras-transformation alters the metabolism of 
phosphatidylethanolamine and phosphatidylcholine in NIH 3T3 fibroblasts. Cell biology 
international. 1999;23(9):603-10. 
74. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid 
metabolism in breast cancer. Cancer Res. 2004;64(12):4270-6. 
75. Gallazzini M, Ferraris JD, Burg MB. GDPD5 is a glycerophosphocholine phosphodiesterase that 
osmotically regulates the osmoprotective organic osmolyte GPC. Proc Natl Acad Sci U S A. 
2008;105(31):11026-31. 
76. Serkova NJ, Glunde K. Metabolomics of cancer. Methods in molecular biology (Clifton, NJ). 
2009;520:273-95. 
77. Shang Q, Xiang J-F, Tang Y-L. NMR-based metabonomics: a useful platform of oncology 
research. Bioanalytical Reviews. 2010;1(2):117-40. 
78. Nordstrom A, Lewensohn R. Metabolomics: moving to the clinic. J Neuroimmune Pharmacol. 
2010;5(1):4-17. 
79. Gowda GA, Zhang S, Gu H, Asiago V, Shanaiah N, Raftery D. Metabolomics-based methods 
for early disease diagnostics. Expert review of molecular diagnostics. 2008;8(5):617-33. 
80. Andrew ER. Magic angle spinning. In Encyclopedia of nuclear magnetic resonance. Chichester: 
Wiley; 1996. 
81. Andrew ER, Bradbury A, Eades RG. Nuclear Magnetic Resonance Spectra from a Crystal 
rotated at High Speed. Nature. 1958;182(4650):1659. 
82. Lowe IJ. Free Induction Decays of Rotating Solids. Phys Rev Lett. 1959;2(7):285. 
83. Sitter B, Sonnewald U, Spraul M, Fjosne HE, Gribbestad IS. High-resolution magic angle 
spinning MRS of breast cancer tissue. NMR Biomed. 2002;15(5):327-37. 
84. Cheng LL, Ma MJ, Becerra L, Ptak T, Tracey I, Lackner A, et al. Quantitative neuropathology 
by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl 
Acad Sci U S A. 1997;94(12):6408-13. 
85. Martinez-Bisbal MC, Marti-Bonmati L, Piquer J, Revert A, Ferrer P, Llacer JL, et al. 1H and 
13C HR-MAS spectroscopy of intact biopsy samples ex vivo and in vivo 1H MRS study of 
human high grade gliomas. NMR Biomed. 2004;17(4):191-205. 
86. Cheng LL, Chang IW, Smith BL, Gonzalez RG. Evaluating human breast ductal carcinomas 
with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J Magn 
Reson. 1998;135(1):194-202. 
87. Cheng LL, Wu C-l, Smith MR, Gonzalez RG. Non-destructive quantitation of spermine in 
human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T. FEBS Lett. 
2001;494(1-2):112-6. 
88. Mark G. Swanson ASZ, Z. Laura Tabatabai, Jeffry Simko, Samson Jarso, Kayvan R. Keshari, 
Lars Schmitt, Peter R. Carroll, Katsuto Shinohara, Daniel B. Vigneron, John Kurhanewicz,. 
Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson 
Med. 2006;55(6):1257-64. 
89. Bathen TF, Sitter B, Sjobakk TE, Tessem MB, Gribbestad IS. Magnetic resonance metabolomics 
of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. Cancer 
Res. 2010;70(17):6692-6. 
 
 
References 
59 
 
90. Moestue SA, Engebraaten O, Gribbestad IS. Metabolic effects of signal transduction inhibition 
in cancer assessed by magnetic resonance spectroscopy. Mol Oncol. 2011;5(3):224-41. 
91. Bathen TF, Jensen LR, Sitter B, Fjosne HE, Halgunset J, Axelson DE, et al. MR-determined 
metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone 
status. Breast Cancer Res and Treat. 2007;104(2):181-9. 
92. Giskeodegard GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjosne HE, et al. Multivariate 
modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome 
Res. 2010;9(2):972-9. 
93. Kemsley EK, Le Gall G, Dainty JR, Watson AD, Harvey LJ, Tapp HS, et al. Multivariate 
techniques and their application in nutrition: a metabolomics case study. Brit J Nutr. 
2007;98(1):1-14. 
94. Liland KH, Almoy T, Mevik BH. Optimal choice of baseline correction for multivariate 
calibration of spectra. Applied spectroscopy. 2010;64(9):1007-16. 
95. Giskeødegård GF, Bloemberg TG, Postma G, Sitter B, Tessem M-B, Gribbestad IS, et al. 
Alignment of high resolution magic angle spinning magnetic resonance spectra using warping 
methods. Anal Chim Acta. 2010;683(1):1-11. 
96. Wong JW, Cagney G, Cartwright HM. SpecAlign--processing and alignment of mass spectra 
datasets. Bioinformatics. 2005;21(9):2088-90. 
97. Savorani F, Tomasi G, Engelsen SB. icoshift: A versatile tool for the rapid alignment of 1D 
NMR spectra. J Magn Reson. 2010;202(2):190-202. 
98. Nielsen N-PV, Carstensen JM, Smedsgaard J. Aligning of single and multiple wavelength 
chromatographic profiles for chemometric data analysis using correlation optimised warping. J 
Chromatogr A. 1998;805(1-2):17-35. 
99. Leardi R, Boggia R, Terrile M. Genetic algorithms as a strategy for feature selection. Journal of 
Chemometrics. 1992;6(5):267-81. 
100. Cho H-W, Kim SB, Jeong MK, Park Y, Ziegler TR, Jones DP. Genetic algorithm-based feature 
selection in high-resolution NMR spectra. Expert Syst Appl. 2008;35(3):967-75. 
101. Westerhuis J, Hoefsloot H, Smit S, Vis D, Smilde A, van Velzen E, et al. Assessment of PLSDA 
cross validation. Metabolomics. 2008;4(1):81-9. 
102. Chong I-G, Jun C-H. Performance of some variable selection methods when multicollinearity is 
present. Chemometr Intell Lab. 2005;78(1-2):103-12. 
103. van Velzen EJJ, Westerhuis JA, van Duynhoven JPM, van Dorsten FA, Hoefsloot HCJ, Jacobs 
DM, et al. Multilevel Data Analysis of a Crossover Designed Human Nutritional Intervention 
Study. J Proteome Res. 2008;7(10):4483-91. 
104. Westerhuis JA, van Velzen EJ, Hoefsloot HC, Smilde AK. Multivariate paired data analysis: 
multilevel PLSDA versus OPLSDA. Metabolomics. 2010;6(1):119-28. 
105. PeakFit Software, http://www.aspiresoftwareintl.com/html/peakfit.html.  [01.June 2009]. 
106. Sitter B, Bathen T, Tessem M, Gribbestad I. High-resolution magic angle spinning (HR MAS) 
MR spectroscopy in metabolic characterization of human cancer. Prog Nucl Magn Reson 
Spectrosc. 2009;54(3-4):239-54. 
107. Kriat M, Confort-Gouny S, Vion-Dury J, Sciaky M, Viout P, Cozzone PJ. Quantitation of 
metabolites in human blood serum by proton magnetic resonance spectroscopy. A comparative 
study of the use of formate and TSP as concentration standards. NMR Biomed. 1992;5(4):179-
84. 
108. Helms G. The principles of quantification applied to in vivo proton MR spectroscopy. Eur J 
Radiol. 2008;67(2):218-29. 
109. Akoka S, Barantin L, Trierweiler M. Concentration Measurement by Proton NMR Using the 
ERETIC Method. Anal Chem. 1999;71(13):2554-7. 
110. Albers MJ, Butler TN, Rahwa I, Bao N, Keshari KR, Swanson MG, et al. Evaluation of the 
ERETIC method as an improved quantitative reference for 1H HR-MAS spectroscopy of 
prostate tissue. Magn Reson Med. 2009;61(3):525-32. 
111. Sitter B, Bathen TF, Singstad TE, Fjosne HE, Lundgren S, Halgunset J, et al. Quantification of 
metabolites in breast cancer patients with different clinical prognosis using HR MAS MR 
spectroscopy. NMR Biomed. 2010;23(4):424-31. 
112. Martinez-Bisbal MC, Monleon D, Assemat O, Piotto M, Piquer J, Llacer JL, et al. Determination 
of metabolite concentrations in human brain tumour biopsy samples using HR-MAS and 
ERETIC measurements. NMR Biomed. 2009;22(2):199-206. 
 
 
References 
60 
 
113. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, et al. Specific P53 
mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat 
Med. 1996;2(7):811-4. 
114. Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, et al. Predictive 
and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast 
Cancer Patients Treated with Epirubicin or Paclitaxel. PloS one. 2011;6(4):e19249. 
115. Thorsen T. Occupied and unoccupied nuclear oestradiol receptor in human breast tumours: 
relation to oestradiol and progesterone cytosol receptors. J Steroid Biochem. 1979;10(6):661-8. 
116. Glunde K, Guggino SE, Solaiyappan M, Pathak AP, Ichikawa Y, Bhujwalla ZM. Extracellular 
acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia (New York, 
NY). 2003;5(6):533-45. 
117. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative 
PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8. 
118. Eilers PHC. Parametric Time Warping. Anal Chem. 2004;76:404-11. 
119. Jordan K, He W, Halpern E, Wu C, Cheng L. Evaluation of Tissue Metabolites with High 
Resolution Magic Angle Spinning MR Spectroscopy Human Prostate Samples After Three-Year 
Storage at- 80° C. Biomark Insights. 2007;2:147. 
120. Mangia A, Chiriatti A, Chiarappa P, Incalza MA, Antonaci G, Pilato B, et al. Touch imprint 
cytology in tumor tissue banks for the confirmation of neoplastic cellularity and for DNA 
extraction. Arch Pathol Lab Med. 2008;132(6):974-8. 
121. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR 
spectra. Magn Reson Med. 1993;30(6):672-9. 
122. Righi V, Roda JM, Paz J, Mucci A, Tugnoli V, Rodriguez-Tarduchy G, et al. 1H HR-MAS and 
genomic analysis of human tumor biopsies discriminate between high and low grade 
astrocytomas. NMR Biomed. 2009;22(6):629-37. 
123. Opstad KS, Bell BA, Griffiths JR, Howe FA. Toward accurate quantification of metabolites, 
lipids, and macromolecules in HRMAS spectra of human brain tumor biopsies using LCModel. 
Magn Reson Med. 2008;60(5):1237-42. 
124. Ziarelli F, Caldarelli S. Solid-state NMR as an analytical tool: Quantitative aspects. Solid State 
Nuc Magn Reson. 2006;29(1-3):214-8. 
125. Wider G, Dreier L. Measuring protein concentrations by NMR spectroscopy. Journal of the 
American Chemical Society. 2006;128(8):2571-6. 
126. Farrant RD, Hollerton JC, Lynn SM, Provera S, Sidebottom PJ, Upton RJ. NMR quantification 
using an artificial signal. Magn Reson Chem. 2010;48(10):753-62. 
127. Gribbestad IS, Sitter B, Lundgren S, Krane J, Axelson D. Metabolite composition in breast 
tumors examined by proton nuclear magnetic resonance spectroscopy. Anticancer res. 
1999;19(3A):1737-46. 
128. Joensuu H, Sailas L, Alanko T, Sunela K, Huuhtanen R, Utriainen M, et al. Docetaxel versus 
docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of 
a randomised trial. Ann Oncol. 2010;21(5):968-73. 
129. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of 
neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28(7):1145-53. 
130. Baek HM, Chen JH, Nie K, Yu HJ, Bahri S, Mehta RS, et al. Predicting pathologic response to 
neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR 
spectroscopy. Radiology. 2009;251(3):653-62. 
131. Jagannathan NR, Kumar M, Seenu V, Coshic O, Dwivedi SN, Julka PK, et al. Evaluation of total 
choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant 
chemotherapy in locally advanced breast cancer. Brit J Cancer. 2001;84(8):1016-22. 
132. Danishad KK, Sharma U, Sah RG, Seenu V, Parshad R, Jagannathan NR. Assessment of 
therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant 
chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging 
(MRSI). NMR Biomed. 2010;23(3):233-41. 
133. Huuse EM, Jensen LR, Goa PE, Lundgren S, Anderssen E, Bofin A, et al. Monitoring the Effect 
of Docetaxel Treatment in MCF7 Xenografts Using Multimodal In Vivo and Ex Vivo Magnetic 
Resonance Methods, Histopathology, and Gene Expression. Transl Oncol. 2010;3(4):252-63. 
 
 
References 
61 
 
134. Jensen LR, Huuse EM, Bathen TF, Goa PE, Bofin AM, Pedersen TB, et al. Assessment of early 
docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo 
HR MAS, and in vivo 1H MRS. NMR Biomed. 2010;23(1):56-65. 
135. Heldahl MG, Lundgren S, Jensen LR, Gribbestad IS, Bathen TF. Monitoring neoadjuvant 
chemotherapy in breast cancer patients: Improved MR assessment at 3 T? J Magn Reson 
Imaging : JMRI. 2011. 34 (3)547-556. 
136. Mols F, Vingerhoets AJJM, Coebergh JW, van de Poll-Franse LV. Quality of life among long-
term breast cancer survivors: A systematic review. Eur J Cancer. 2005;41(17):2613-9. 
137. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between 
glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9(6):425-34. 
138. Rundqvist H, Johnson RS. Hypoxia and Metastasis in Breast Cancer Diverse Effects of Hypoxia 
on Tumor Progression. In: Simon MC, editor.: Springer Berlin Heidelberg; 2010. p. 121-39. 
139. Milani M, Harris AL. Targeting tumour hypoxia in breast cancer. Eur J Cancer. 
2008;44(18):2766-73. 
140. Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL. Anthracycline chemotherapy inhibits 
HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. 
Proc Natl Acad Sci U S A. 2009;106(7):2353-8. 
141. Locasale J, Cantley L. Altered metabolism in cancer. BMC Biology. 2010;8(1):88. 
142. Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, Borresen-Dale AL, et al. Distinct 
choline metabolic profiles are associated with differences in gene expression for basal-like and 
luminal-like breast cancer xenograft models. BMC cancer. 2010;10:433. 
143. Ramirez de Molina A, Banez-Coronel M, Gutierrez R, Rodriguez-Gonzalez A, Olmeda D, 
Megias D, et al. Choline kinase activation is a critical requirement for the proliferation of 
primary human mammary epithelial cells and breast tumor progression. Cancer Res. 
2004;64(18):6732-9. 
144. Baek H-M, Yu HJ, Chen J-H, Nalcioglu O, Su M-Y. Quantitative correlation between 1H MRS 
and dynamic contrast-enhanced MRI of human breast cancer. Magn Reson Imaging. 
2008;26(4):523-31. 
145. Chen JH, Mehta RS, Baek HM, Nie K, Liu H, Lin MQ, et al. Clinical characteristics and 
biomarkers of breast cancer associated with choline concentration measured by 1H MRS. NMR 
Biomed. 2011;24(3):316-24. 
146. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of 
human breast tumours. Nature. 2000;406(6797):747-52. 
147. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns 
of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the 
National Academy of Sciences of the United States of America. 2001;98(19):10869-74. 
148. Borgan E, Sitter B, Lingjaerde OC, Johnsen H, Lundgren S, Bathen TF, et al. Merging 
transcriptomics and metabolomics--advances in breast cancer profiling. BMC cancer. 
2010;10:628. 
149. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, et al. Alterations of 
choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005;65(20):9369-
76. 
150. Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Humpfer E, Spraul M, et al. Metabolic 
profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) 
NMR spectroscopy. J Proteome Res. 2010;9(1):319-32. 
151. Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, et al. 
Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues 
using 1H HR-MAS total correlation spectroscopy. Magn Reson Med. 2008;60(1):33-40. 
152. Lang Q, Zhang H, Li J, Yin H, Zhang Y, Tang W, et al. Cloning and characterization of a human 
GDPD domain-containing protein GDPD5. Mol Biol Rep. 2008;35(3):351-9. 
153. Sakagami H, Aoki J, Natori Y, Nishikawa K, Kakehi Y, Arai H. Biochemical and molecular 
characterization of a novel choline-specific glycerophosphodiester phosphodiesterase belonging 
to the nucleotide pyrophosphatase/phosphodiesterase family. J Biol Chem. 2005;280(24):23084-
93. 
154. Nakagami K, Uchida T, Ohwada S, Koibuchi Y, Morishita Y. Increased choline kinase activity 
in 1,2-dimethylhydrazine-induced rat colon cancer. Jpn J Cancer Res. 1999;90(11):1212-7. 
 
 
References 
62 
 
155. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, 
Bonilla F, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived 
cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun. 
2002;296(3):580-3. 
156. Foster DA, Xu L. Phospholipase D in cell proliferation and cancer. Mol Cancer Res. 
2003;1(11):789-800. 
157. Shah T, Wildes F, Penet M-F, Winnard PT, Glunde K, Artemov D, et al. Choline kinase 
overexpression increases invasiveness and drug resistance of human breast cancer cells. NMR 
Biomed. 2010;23(6):633-42. 
158. Al-Saffar NM, Troy H, Ramirez de Molina A, Jackson LE, Madhu B, Griffiths JR, et al. 
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase 
inhibitor MN58b in human carcinoma models. Cancer Res. 2006;66(1):427-34. 
 
 
Paper I
 
Is not included due to copyright 
 
Paper II
 
1Prognostic value of metabolic response in breast cancer patients receiving
neoadjuvant chemotherapy
Maria D. Cao*,1, Guro F. Giskeødegård*,1, Tone F. Bathen1,2, Beathe Sitter1,2, Anna Bofin3,
Per E. Lønning4,5, Steinar Lundgren1,6,7, Ingrid S. Gribbestad1
* shared first authorship
1Department of Circulation and Medical Imaging, Norwegian University of Science and 
Technology (NTNU), 7489 Trondheim, Norway
2St Olavs University Hospital, Trondheim, Norway
3Department of Laboratory Medicine, Children’s and Women’s Health, NTNU, 7489 
Trondheim, Norway
4Department of Oncology, Haukeland University Hospital, 5021 Bergen, Norway
5Section of Oncology, Institute of medicine, University of Bergen, 5020 Bergen, Norway 
6Department of Oncology, St. Olavs Hospital, University Hospital of Trondheim, 7006 
Trondheim, Norway
7Department of Cancer Research and Molecular Medicine, NTNU, 7489 Trondheim, Norway
Corresponding author: Maria D. Cao, Department of Circulation and Medical Imaging, The 
Faculty of Medicine, NTNU, MTFS, Postboks 8905, N-7489 Trondheim, Norway. Tel.: +47 
73598121,  fax: +47 73551350, e-mail address: maria.d.cao@ntnu.no.
2Abstract
BACKGROUND: Today's clinical diagnostic tools are insufficient for giving accurate 
prognosis to breast cancer patients. The aim of our study was to examine the tumor metabolic 
changes in patients with locally advanced breast cancer caused by neoadjuvant chemotherapy 
(NAC), relating these changes to clinical treatment response and long-term survival.
METHODS: Patients (n=89) participating in a randomized open-label multicenter study were 
allocated to receive either NAC as epirubicin or paclitaxel monotherapy. Biopsies were 
excised pre- and post-treatment, and analyzed by high resolution magic angle spinning 
magnetic resonance spectroscopy (HR MAS MRS). The metabolite profiles were examined 
by paired and unpaired multivariate methods and findings of important metabolites were 
confirmed by spectral integration of the metabolite peaks.
RESULTS: All patients had a significant metabolic response to NAC, and pre- and post-
treatment spectra could be discriminated with 87.9%/68.9% classification accuracy by 
paired/unpaired partial least squares discriminant analysis (PLS-DA) (p<0.001). Similar
metabolic responses were observed for the two chemotherapeutic agents. The metabolic 
responses were related to patient outcome. Non-survivors (<5 years) had increased tumor 
levels of lactate (p=0.004) after treatment, while surviYRUV5 years) experienced a decrease 
in the levels of glycine (p=0.047) and choline-containing comSRXQGV S0.013) and an 
increase in glucose (p=0.002) levels. The metabolic responses could not be related to clinical 
treatment response.
CONCLUSIONS: The differences in tumor metabolic response to NAC were associated with 
breast cancer survival, but not to clinical response. Monitoring metabolic responses to NAC 
by HR MAS MRS may provide information about tumor biology related to individual 
prognosis.
3Background
The prognosis of patients with locally advanced breast cancer varies largely due to the 
heterogeneity of the disease, and 5-year survival rates from 50-80% have been reported [1].
Neoadjuvant chemotherapy (NAC) has been established as a standard treatment for locally 
advanced breast cancer, with anthracyclines and taxanes being among the most frequently 
used agents. NAC is provided to make primarily inoperable tumors resectable, and will also 
increase the rate of breast-conserving surgery without any significant increase in local or 
distal recurrence [2, 3]. Studies investigating the metabolic responses and chemoresistance to 
single or a combination of drugs are important for effective treatment and better patient 
outcome.
Patients with a pathological complete response (pCR) after NAC have improved outcome 
compared to patients with residual disease, thus treatment response is a prognostic indicator. 
However, only ~20% of patients will achieve a pCR to NAC [4]. Other prognostic factors of 
breast cancer include axillary lymph node status, tumor size, Her-2 overexpression, 
histopathological grade, and hormone receptor status. The status of Her-2 and hormone 
receptors is also predictive of treatment response. Identification of other markers for 
prognosis and treatment response may help stratify patients for better individualized 
treatment. 
Several studies have shown altered metabolism in cancer compared to normal tissue. Elevated 
levels of total choline-containing compounds (tCho) are frequently observed in cancer, and 
may serve as magnetic resonance spectroscopy (MRS) markers for malignancy, both in vivo
and ex vivo [5, 6]. The tCho signal constitutes signals from glycerophosphocholine (GPC), 
phosphocholine (PC) and free choline (Cho) which are involved in phospholipid metabolism 
through the Kennedy pathway. A decreased level of tCho detected by in vivo MRS has been 
suggested as a possible marker for treatment response [7, 8]. Altered concentrations of other 
tissue metabolites, such as increased levels of lactate, have also been associated with 
malignancy [9, 10]. Elevated lactate levels may be related to hypoxia, a common feature of 
solid tumors where glucose is catabolised to lactate due to the lack of oxygen. Also under 
conditions with sufficient oxygen levels, cancer cells may convert glucose to lactate, 
described as the Warburg effect. 
4High resolution magic angle spinning (HR MAS) MRS is a non-destructive technique 
providing highly resolved MR spectra of intact tissues with minimal sample preparation. HR 
MAS MR spectra provide an overview of the different metabolites that are present in a tissue 
sample, and can give insight into the complex processes leading to cancer and other diseases. 
More than 30 metabolites have been identified in breast tissue using HR MAS MRS [11].
Systematic studies of the metabolic state of biological systems using multivariate analysis 
methods are referred to as metabolomics. MR metabolomics studies of breast cancer have 
revealed correlations between tissue metabolic profiles and clinical prognostic factors such as 
hormone receptor status, grade and lymphatic spread [12-14]. Long-term survival of breast 
cancer patients has been successfully predicted from breast cancer tissue using multivariate 
classification models [15, submitted manuscript Giskeødegård et al]. The purpose of this 
study was to examine the metabolic changes in breast cancer tissues resulting from treatment 
with NAC, and to relate these changes to treatment response and long-term survival. This is 
the first study to investigate the metabolic response of NAC in a large breast cancer cohort
using ex vivo MRS.
5Methods
Patient and tumor characteristics 
We examined a subcohort of breast cancer patients (n = 89) from a larger open-label 
multicenter study where patients were randomly allocated to receive NAC treatment with 
either anthracycline (epirubicin, 90 mg/m2) or taxane (paclitaxel, 200 mg/m2) monotherapy 
[16]. The patients were given subsequent adjuvant endocrine treatment according to 
guidelines from the Norwegian Breast Cancer Group. The inclusion criteria and treatment 
protocol are fully described elsewhere [16]. Briefly, female breast cancer patients at pre/post 
PHQRSDXVDO DJH   \HDUV ZLWK ORFDOO\ DGYDQFHG VWDJH ,,, 73/4 and/or N2) non-
inflammatory breast cancer with or without limited distant metastasis were recruited in the 
period 1997-2003. The patients were treated every third week for four cycles. Patients 
showing a non-satisfactory response were assigned to the opposite treatment.  From each 
patient, an incisional biopsy was taken before treatment with NAC and a post-treatment 
biopsy was excised during surgical removal of the tumor. The biopsies were immediately 
snap-frozen and stored in liquid nitrogen in a biobank until use. A part of the pre-treatment 
tumor biopsy was obtained for routine pathological diagnosis and hormone status assignment. 
Estrogen (ER) and progesterone receptor (PgR) status were determined by 
LPPXQRKLVWRFKHPLFDO VWDLQLQJ SRVLWLYH   VWDLQLQJ FHOOV The study was approved by 
The Regional Committee for Medical and Health Research Ethics (Norwegian Health Region 
III) and informed written consent was obtained from all patients
Response and survival evaluation
Response to treatment was evaluated using the WHO criteria by the UICC system [17].
Treatment response was assessed clinically by comparing caliper measurements prior to NAC 
treatment and after the last cycle. In the subcohort included in this study, the patients were 
classified to have eitKHUSDUWLDOUHVSRQVHUHGXFWLRQLQWXPRUVL]HWKHSURGXFWRIWKH
two largest tumor diameters), but not complete response) or stable disease (< 50 % reduction 
WR  25 % increase in tumor size). Patients deceased within 5 years after diagnosis were 
classified as non-survivors whereas patients surviving 5 years or more were classified as 
survivors.
6Histopathological examinations
Prior to HR MAS MRS analysis, imprint cytology smears were prepared from the tissue 
samples and stained with the May-Grünwald-Giemsa stain (Color-Rapid, Med-Kjemi, 
Norway). Confirmation of tumor cell content was determined microscopically by a 
cytopathologist.
HR MAS MRS experiments
HR MAS MRS analyses were performed on a Bruker Avance DRX600 spectrometer (Bruker 
Biospin GmbH, Germany) equipped with a 1H/13C MAS probe with gradient. The run order of 
the samples was randomized (www.random.org) and blindly analyzed during 18 days. Each 
sample (15.1±2.8 mg) was cut to fit a 30 ȝO OHDN-proof disposable insert (Bruker Biospin 
Corp, USA) and added pKRVSKDWHEXIIHUHGVDOLQH3%6ȝOLQ'2O containing trimethylsilyl 
tetradeuteropropionic acid (TSP, 98.2 mM) for chemical shift referencing. Samples were spun 
at 5 kHz and spectra were recorded within 31 minutes per sample at 4°C to minimize tissue 
degradation. Spin-echo spectra (cpmgpr; Bruker) were recorded as previously described [14].
Data preprocessing
Twenty eight spectra were excluded from further studies due to low tumor cell content. The 
resulting data set consisted of 150 spectra from 85 patients (80 pre-treatment and 70 post-
treatment spectra).  Characteristics of the included patients and tumors are listed in Table 1. 
The MR spectra were Fourier transformed into 128 K after 0.3 Hz exponential line 
broadening. Chemical shifts were referenced to the TSP peak at 0 ppm. The spectral region 
between 4.69-1.45 ppm, excluding the water peak and large lipid residuals, was chosen for 
analysis. Signals from ethanol pollutions between 3.69-3.57 ppm were removed together with 
lipid residual signals between 3.01-1.52 ppm. The spectra were baseline corrected using 
asymmetric least squares [18] with parameters Ȝ  H DQG S    DQG WKHPLQLPXP
value of each spectrum was set to zero by subtracting the lowest value. The spectra were 
normalized to equal total area, and peak aligned using icoshift [19].
7Multivariate data analysis
Partial least squares (PLS) analysis is a regression method for analysis of collinear data with 
numerous variables. The method is based on extraction of underlying structures, or latent 
variables (LVs), that maximize the covariance between X (the spectra) and a response 
variable Y [20].  PLS discriminant analysis (PLS-DA) attempts to discriminate between 
distinct classes. PLS-DA was performed in Matlab R2009a (The Mathworks, Inc., USA)
using PLS_Toolbox 6.2.1 (Eigenvector Research, USA). A PLS-DA model was built on 
mean-centred spectra from randomly chosen training samples (90 % of the patients) and used 
to predict the status of test samples (the remaining 10 %). This procedure was repeated 20 
times and the average classification results were calculated. The number of LVs to use was 
chosen by cross-validation of the whole data set and used for all repetitions to avoid biased 
results. The importance of each variable in the loadings of the PLS-DA was evaluated by 
variable importance in the projection (VIP) scores [21]. The VIP score positively reflects the 
variable’s influence on the classification, and variables with a score greater than one are 
generally considered important [21, 22]. To evaluate the statistical significance of the
classification results, permutation testing was performed [23]. In permutation testing, the class 
labels are permuted to resemble random classification. It is then possible to examine if the 
achieved prediction results of the original data set are significantly different than random 
predictions. The data set with the permuted class label was divided into training and test sets 
repeated 20 times as described for the original data set, and the average results were 
calculated. The permutation procedure was repeated 1000 times, and the prediction error of 
the original data set was compared to the distribution of prediction errors from the 
permutation. P-YDOXHVZHUHFRQVLGHUHGVLJQLILFDQW
Multilevel PLS-DA [24, 25] is an extension of ordinary PLS-DA which can be used as a 
paired analysis for multivariate data. This analysis can only be used when the data has a 
multilevel structure, i.e. when interventions are evaluated on the same subject. In multilevel 
PLS-DA, the between subject variation is separated from the within subject variation. This is 
useful in metabolic profiling as the variation between subjects, resulting from differences in 
age, disease state, genetics and other factors, can obscure the metabolic changes caused by the 
intervention. The between subject variation is described by the average of the two 
observations from one subject, whereas the within subject variation is described by the net 
difference between them. Multilevel PLS-DA was used to examine metabolic changes in the 
8spectra resulting from NAC treatment. The split-up of variation was done using algorithms 
made available by van Velzen et al [24]. Further PLS-DA classifications of the within subject 
variation were performed using PLS_Toolbox as described for the unpaired analyses. The net 
difference of the spectra pre minus post treatment (positively representing the metabolites 
higher expressed before treatment) is annotated as control, while the net difference post minus 
pre treatment (positively representing the metabolites higher expressed after treatment) is 
annotated as treatment. More specifically, 
control = A – B
treatment = B – A (eq. 1)
where the matrix A represents pre-treatment spectra, and matrix B represents the post-
treatment spectra. 
Univariate data analysis
To further validate the important metabolites from the PLS-DA models, relative intensities 
were found by integrating the peak areas of spectra normalized to equal total areas after 
removal of lipid residuals (Matlab R2009a, The Mathworks, Inc., USA). Normalization of 
spectra with the lipid residual signals removed will correct for differences in sample size and 
tumor cell content, as it can be assumed that most of the lipid signals from breast samples do 
not originate from cancer cells. Group differences were statistically tested by Wilcoxon rank 
sum tests or Wilcoxon sign rank for paired analyses, and considered significant if the p-values 
ZHUH
9Results
Metabolic response to neoadjuvant chemotherapy
All classification results are summarized in Table 2.  An unpaired PLS-DA of the pre- and 
post-treatment spectra of the whole data set showed a significant difference in the metabolite 
profiles in response to NAC treatment, indicating a metabolic response to NAC in all patients.
However, the specificity of the classification was low (57.1%). When comparing the 
classification errors of PLS-DA and paired multilevel PLS-DA from 20 different test sets, the 
multilevel PLS-DA with split-up of the variation decreased the classification error 
significantly (Wilcoxon rank sum test, p < 0.001), showing the beneficial effect of the paired 
analysis. Treatment and control spectra could be separated with a sensitivity and specificity of 
87.9%. Figure 1A shows the scores and loadings of the multilevel PLS-DA. Lactate and PC 
were of high importance for the discrimination according to the VIP scores in the loadings. 
The levels of lactate and glycine appear to be increased in response to treatment, while the 
levels of PC are markedly decreased for some patients. In addition, GPC levels were 
decreased in response to treatment. No clustering according to the given chemotherapeutic 
agents could be seen in the multilevel PLS-DA score plot (results not shown), thus the 
metabolic treatment effects of epirubicin and paclitaxel appear to be indistinguishable. 
No differences in metabolic response between clinical response groups
The patients were divided into two groups according to their clinical response (partial 
response or stable disease), and multilevel PLS-DA was performed on each group separately 
in order to discover potential differences in metabolic treatment response between the groups. 
Both for patients with partial response and stable disease there was a significant change in the 
tumor metabolism in response to NAC treatment, and treatment spectra could be 
discriminated from controls with high sensitiYLW\ DQG VSHFLILFLW\   7KHPHWDEROLF
response to NAC as observed in the loading plots was similar for both subgroups, resembling 
the changes observed for the whole data set (results not shown). Thus, no difference in the 
metabolic response could be detected between patients with stable disease and partial 
response.  
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Different metabolic responses correlate with survival
Accordingly the patients were divided into two groups according to their survival status (5-
year survivors or non-survivors). Both for survivors and non-survivors there was a clear 
change in the tumor metabolism in response to NAC treatment (Figure 1B and C), and 
WUHDWPHQWVSHFWUDFRXOGEHGLVFULPLQDWHGIURPFRQWUROVZLWKKLJKVHQVLWLYLW\DQGVSHFLILFLW\
82.5%).  However, the metabolic treatment response appears to differ between survivors and 
non-survivors. 
The loadings showed unchanged lactate levels in response to treatment in survivors, while 
lactate increased in non-survivors with high importance for the discrimination according to 
the VIP scores. This was confirmed by comparison of the relative intensities from metabolite 
integrals, showing a significant increase in lactate levels in response to treatment in non-
survivors (p = 0.004) but not in survivors (Table 3). 
Glycine appears to be decreased in survivors according to the loadings, and the difference in 
relative intensities before and after treatment was significant (p = 0.047). For non-survivors, 
the glycine level appears to be high in some samples from both the control and the treatment 
group; hence the role of glycine in the loading plot is more difficult to interpret. The glycine 
change from integrated relative intensities was not significant in non-survivors, with a mean 
value close to zero. 
GPC levels were decreased in the loading plot of survivors with VIP scores showing high 
importance, while changes in GPC levels in non-survivors were less important for the 
discrimination. Accordingly, the relative intensities of GPC were significantly lower in 
response to treatment in survivors (p < 0.001) but not in non-survivors. 
The loadings show decreased levels of PC in response to treatment in both survivors and non-
survivors. However, the change in PC relative intensities was only significant for survivors (p 
< 0.001),  but not for non-survivors, possibly due to a high standard error.  
Relative intensities of Cho levels were significantly decreased in survivors (p = 0.013) in 
response to treatment, but only a trend of decreased Cho levels was seen in non-survivors (p = 
11
0.084). In addition, glucose was significantly increased in survivors (p = 0.002). Cho and 
glucose were not protruding in the loadings, possibly due to low intensity values.  
As an overall measure of the partly overlapping choline-containing metabolite peaks (GPC, 
PC, and Cho), the changes in relative intensities of tCho were calculated. Survivors had a 
significant decrease in tCho levels in response to treatment (p < 0.001), while a trend of 
decreased tCho levels were detected in non-survivors (p = 0.091). 
Metabolic traits at pre- and post-treatment
A PLS-DA of the post-treatment spectra showed a significant difference in the metabolite 
profiles of 5-year survivors and non-survivors after treatment with 70.1% correct 
classification (Table 2). According to the scores and loadings shown in Figure 2, the tumors 
of non-survivors appear to have more of the metabolites lactate and glycine, and less GPC and 
taurine than survivors post-treatment. PC appears to be present in high levels in some samples 
of both survivors and non-survivors. The glycine level was denoted to be of major importance 
according to the VIP scores, and the relative intensities of glycine were significantly higher in 
non-survivors compared to survivors post-treatment (p = 0.033, Table 4). Similarly, a trend of 
higher relative intensities of lactate was observed in non-survivors (p = 0.089). No significant 
differences in the relative intensities of taurine and GPC were observed, however differences 
in the levels of tCho approached significance (p = 0.075) with non-survivors having higher 
relative intensities than survivors post-treatment.
The metabolic differences between survivor and non-survivors were not seen pre-treatment as 
the multivariate model could not discriminate the two outcome groups (model not valid). 
None of the metabolites showed significant differences in relative intensities between 
survivors and non-survivors pre-treatment (Table 4). 
No significant differences in the metabolite profiles at pre- or post-treatment were detected 
between patients with partial responders and stable disease by PLS-DA. Post-treatment 
spectra from patients treated with Epirubicin and Paclitaxel could not be discriminated by 
PLS-DA, further confirming the similarity of the metabolic response of the two 
chemotherapeutic agents that were used in this study. 
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Discussion 
In this study we examined the metabolic effect of NAC treatment in patients with locally 
advanced breast cancer. By comparing MR spectra of biopsies taken pre- and post-treatment, 
significant metabolic changes in response to treatment were found both by paired and 
unpaired multivariate models. The results using paired multilevel PLS-DA were however 
superior to those of unpaired PLS-DA, thus taking advantage of the multilevel structure in the 
data set was clearly beneficial. 
Epirubicin and Paclitaxel appear to affect the metabolism of the tumor cells in the same 
manners, as evidenced both by indistinguishable metabolic responses and similar metabolic 
traits of the post-treatment spectra. Anthracyclines work by interfering with the synthesis and 
function of DNA, while taxanes stabilize the microtubules; thereby inhibiting cell division 
[26, 27]. However, both treatments will eventually result in cell death. This might explain 
why the two agents appear to have similar metabolic responses. 
Interestingly all patient in our study cohort showed clear changes in the metabolite profiles in 
response to treatment, including also patients categorized to have a clinically stable disease. 
No differences in the metabolic responses of the clinical response groups were detected. 
However, when examining the metabolic changes in survivors and non-survivors 
independently, a difference in the metabolic response to NAC was seen. Non-survivors had a 
significant increase in lactate levels in response to treatment, while survivors showed no
change in lactate levels. As a result, a trend of higher levels of lactate was detected in non-
survivors compared to survivors post-treatment. Increased lactate levels may be a marker for 
tumor aggressiveness as high levels of lactate have been correlated with low survival rates,
high incident of distant metastasis and recurrence, and increased risk of radiation resistance in 
several types of cancer [28-30]. Modification of cell energy metabolism is typically observed 
in malignant tumors and is suggested as an emerging hallmark of cancer [31]. Under 
normoxic conditions, cancer cells can reprogram their energy metabolism to largely depend 
on aerobe glycolysis as their primary energy pathway resulting in increased lactate 
production; the so-called Warburg effect. It is not fully known why cancer cells prefer aerobe 
glycolysis over complete oxidation as this would produce far more ATP. It has been 
hypothesized that lactate may enhance the invasiveness of tumor cells and the resulting low 
pH may help tumor cells evading tumor-attacking immune cells [32].
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In addition to aerobe glycoysis, breast cancer cells are often hypoxic due to poor blood supply 
[33]. It can be assumed that the large tumors of patients with locally advanced breast cancer 
will be affected by hypoxia. Hypoxia can induce the transcription factor hypoxia inducible 
factor-Į +L)-Į ZKLFK LQ WXUQ XSUHJXODWHV PXOWLSOH JHQHV LQYROYHG LQ WKH JO\FRO\WLF
pathway, angiogenesis, cell proliferation, and other mechanisms [33-35]. Furthermore HIF-Į
promotes transcription of lactate dehydrogenase (LDH) and lactate monocarboxylate 
transporters (MCT), and thus plays an important role in the production and efflux of lactate in 
cancer cells [36, 37]. Inhibition of LDH by small interfering RNA (siRNA) in mouse breast 
tumors has been shown to reduce the glycolytic activity associated with a decrease in tumor 
proliferation and tumorigenic potential [38]. Thus we can suggest that the increased levels of 
lactate after NAC treatment observed in non-survivors may reflect enhancement of aerobe 
glycolytic activity and/or hypoxic tumor responses that confer higher tumor malignancy and 
poor prognosis. In coherence, the glucose levels were increased in response to treatment in 
survivors but not in non-survivors. Increased glucose may be indicative of decreased aerobe
glycolysis and tumor hypoxic response favorable of long term breast cancer survival.
Survivors had a significant decrease in glycine as a response to treatment, while it remained 
unchanged in non-survivors. This was reflected in the post-treatment spectra, showing 
significantly lower levels of glycine in survivors. In a previous study, we also found 
decreased glycine levels after NAC to be associated with long term breast cancer survival 
[15]. The biological role of glycine in tumor malignancy is still unclear. Several studies have 
elucidated the biomarker potential of glycine in human brain tumors, where it was found to 
positively correlate with tumor grade [39, 40]. Higher levels of glycine have also been 
detected in pre-clinical studies of the more aggressive basal-like breast cancer model 
compared to the luminal-like model [41]. In patients, high glycine levels detected in 
malignant breast tumors have been correlated with poor prognosis [42]. Glycine is mainly 
synthesized from 3-phosphoglycerate, an intermediate of the glycolysis. In addition, glycine 
can be synthesized from Cho through the glycine-betaine pathway. We can postulate that the 
decreased glycine levels after NAC treatment detected in survivors are caused by altered 
glycolysis and/or reduced Cho levels associated with reduced tumor aggressiveness.
A significant decrease of GPC, PC, Cho levels and the combined tCho level was detected in
survivors in response to treatment, whereas non-survivors experienced only a trend of 
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decrease in Cho and tCho levels. As a result, lower tCho levels in survivors compared to non-
survivors post-treatment approached significance. In a previous publication, we showed that 
GPC and Cho concentrations significantly decreased in patients with long-WHUPVXUYLYDO
years), while non-survivors (< 5 years) had no significant changes in choline phospholipid 
metabolites in response to NAC [15]. Choline phospholipid metabolites are important 
biological compounds in cell membrane synthesis and turnover. In addition, tCho levels have 
been associated with increased malignancy and activation of oncogenic signaling in breast 
cancer cells [43, 44]. Higher tCho concentrations have been detected in high-grade breast 
tumors and tumors with higher pharmacokinetic parameters measured with dynamic contrast 
enhanced MR imaging, indicating a correlation between choline phospholipid metabolism and 
tumor malignancy and angiogenesis [45, 46]. As previously mentioned, cancer cells may 
undergo adaptive responses to hypoxia by inducing HiF-Į,QFUHDVHGW&KROHYHOVDQGFKROLQH
kinase alpha (CHKA) expressions has been detected in prostate cancer cells and xenografts 
models under hypoxic compared to normoxic conditions [47]. In the same study, the authors 
found hypoxic tumor regions to be co-localized with regions of high tCho, which possibly 
occurred through the up-regulation of CHKA by HiF-Į &+.$ LV NQRZQ WR SOD\ DQ
important role in malignant transformation in several types of cancer [48]. Overexpression of 
CHKA and elevated PC and tCho levels of breast cancer cells have been associated with 
increases invasiveness and drug resistance [49]. Decreased choline phospholipid metabolism 
after NAC treatment may be associated with lower malignancy that potentially can be used as 
a predictor of breast cancer survival.
The metabolic responses to NAC treatment appear to be similar in patients with partial 
response and stable disease. None of the patients in this study had a progressive disease, 
whereas patients with a complete response would not have any tumor tissue left for a post-
treatment biopsy. By definition the group with stable disease can have up to 50% reduction in 
tumor volume, and indeed only two patients in this study had an equal or increased tumor size 
after NAC. In that respect, almost all patients had a biological effect of the treatment although 
the tumor reduction was small for patients with a stable disease. It is conceivable that a cohort 
including also patients with progressive disease would reveal clearer differences in metabolic 
response between the clinical response groups. It is however noteworthy that all patients in 
this study in general had a decrease in tCho after NAC, as tCho is suggested as an in vivo
biomarker for clinical treatment response. 
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In this patient cohort, the prediction of overall survival was accomplished with 70.1% 
classification accuracy using post-treatment spectra, but no prognostic information could be 
extracted from the pre-treatment spectra. This shows that the difference between survivors 
and non-survivors post-treatment results from a metabolic response to the treatment. The 
observed higher levels of lactate and glycine in non-survivors compared to survivors support 
our previous studies postulating high lactate and glycine levels to be predictive of low breast 
cancer survival rates (< 5 years).
Prediction of survival in patients receiving NAC is challenging. As NAC will downstage and 
potentially completely remove the disease, standard prognostic indicators such as tumor size 
and lymph node status are no longer fully applicable after NAC. Several studies have shown 
that a pathological complete response after NAC is associated with better survival rates [4].
However, approximately 80% of patients will have residual tumor in the breast after treatment 
[4]. Our study shows that the metabolic response to treatment may be an indicator of patient 
prognosis.
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Conclusions
By comparing HR MAS MR spectra from biopsies excised before and after NAC treatment,
we have revealed significant metabolic changes in breast cancer tumors as a response to 
treatment. Different metabolic responses could be related to patient outcome, but did not 
separate patients with partial response from those with stable disease. Non-survivors had
increased tumor levels of lactate after treatment, while survivors experienced a decrease in the 
levels of glycine and choline-containing compounds. These differences in tumor response 
may reflect tumor aggressiveness associated with breast cancer survival. Monitoring 
metabolic responses to NAC by HR MAS MRS may provide information about tumor 
biology related to prognosis, and help identify pathways for targeted therapies. 
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Table 1 Patient and tumor characteristics 
Survivors Non-survivors NA*
(n=60) (n=23) (n=2)
Mean age (±SD) years 51.1±10.6 49.3±8.3 46.4±2.6
Mean tumor dimensions
(mean ±SD)
mm 67.9x67.9
±18.0x19.8
78.6x77.3
±22.0x24.0
65.0x51.5
±7.1x26.2
NAC treatment Epirubicin
Paclitaxel
Both1
25
23
12
8
5
10
-
2
-
Treatment
response
Partial response
Stable disease
40
20
11
12
1
1
AJCC IIB
IIIA
IIIB
IV
21
25
12
2
7
11
2
3
1
1
-
-
ER status +
-
unknown
41
19
-
7
15
1
2
-
-
PgR status +
-
unknown
32
28
-
14
18
1
2
-
-
Nodes +
-
32
28
14
9
1
1
Metastasis +
-
2
58
2
21
0
2
*NA, not applicable - One patient without following up and one patient dead by other causes;
AJCC, American Joint Committee on Cancer; Both1, sequential treatment with Epirubicin and 
Paclitaxel 
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Table 2 Classification results from PLS-DA and multilevel PLS-DA
Class. 
model
No. of 
LVs
Variance
X/Y
(%)
Sensitivity/
Specificity 
(%)
Class. 
accuracy
(%)
Permutation
p-value
Paired 
data All samples         
Control vs 
Treatment (n=65p)
Multilevel 
PLS-DA 2 58.9/50.9 87.9/87.9 87.9 <0.001
Partial response   Control vs Treatment (n=37p)
Multilevel 
PLS-DA 2 55.7/61.7 80.0/80.0 80.0 <0.001
Stable disease Control vs Treatment (n=28p)
Multilevel 
PLS-DA 2 63.2/61.3 88.7/88.7 88.7 <0.001
Survivors           Control vs Treatment (n=44p)
Multilevel 
PLS-DA 2 60.0/50.5 83.0/83.0 83.0 <0.001
Non-survivors   Control vs Treatment (n=19p)
Multilevel 
PLS-DA 2 70.6/63.9 82.5/82.5 82.5 0.006
Unpaired
data All samples
Pre- vs 
Post-treatment (n=65p) PLD-DA 2 50.3/29.2 80.7/57.1 68.9 <0.001
Pre-treatment Partial response vsStable disease
(n=48) 
(n=32) PLS-DA 2 51.5/19.3 56.7/60.2 58.4 0.231
Post-treatment Partial response vsStable disease
(n=41) 
(n=29) PLS-DA NaN - - - -
Pre-treatment Survivors vsNon-survivors 
(n=57)
(n=20) PLS-DA NaN - - - -
Post-treatment Survivors vsNon-survivors 
(n=47) 
(n=21) PLS-DA 3 62.8/32.1 58.4/75.3 70.1 0.009
Post-treatment Epirubicin vsPaclitaxel
(n=29)
(n=23) PLS-DA 2 45.7/26.8 45.0/48.3 46.5 0.245
The sensitivity is for detecting a treatment/stable disease/non-survivor/Paclitaxel spectrum; Variance X/Y, amount of variance from X/Y explained 
by the model; NaN, no valid model; p, pairs.
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Table 3 Changes in relative intensities of metabolites in response to NAC
Survivors Non-survivors
Metabolite ppm Mean ± SE p-value Mean ± SE p-value
Lactate 4.08-4.13 2.8 ± 15.3 0.815 97.1 ± 26.4 0.004**
Glycine 3.54-3.56 -19.6 ± 8.0 0.047* 0.8 ± 14.3 0.601
GPC 3.22-3.24 -59.6 ± 14.6 < 0.001** -11.8 ± 15.7 0.469
PC 3.21-3.22 -95.4 ± 24.3 < 0.001** -67.4 ± 44.2 0.227
Cho 3.20-3.21 -16.6 ± 6.3 0.013* -17.8 ± 6.3 0.084
tCho 3.20-3.24 -167.2 ± 36.7 < 0.001** -95.3 ± 57.5 0.091
Taurine 3.40-3.43 -0.8 ± 13.2 0.861 6.9 ± 12.5 0.398
ȕ-Glucose 4.61-4.64 17.8 ± 5.1 0.002** -0.2 ± 8.8 0.841
The values (post- minus pre-treatment) of relative intensities are integrated peak areas from spectra normalized to equal total 
areas. Wilcoxon sign rank tests were used for paired statistical analyses. *p < 0.05, ** p < 0.01.
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Table 4 Relative intensities of metabolites at pre- and post-treatment
Pre-treatment (mean ± SE) Post-treatment (mean ± SE)
Metabolites ppm Survivors Non-
survivors
p-value Survivors Non-
survivors
p-value
Lactate 4.08-4.13 185.8 ± 11.4 164.6 ± 13.8 0.534 196.2 ± 12.7 250.6 ± 26.0 0.089
Glycine 3.54-3.56 115.0 ± 6.4 120.8 ± 11.0 0.542 91.2 ± 4.1 111.4 ± 8.4 0.033*
GPC 3.22-3.24 167.3 ± 12.4 170.1 ± 23.9 0.949 115.6 ± 6.7 153.9 ± 24.1 0.144
PC 3.21-3.22 247.9 ± 17.0 285.4 ± 34.9 0.338 158.0 ± 16.1 205.5 ± 28.1 0.105
Cho 3.20-3.21 95.4 ± 3.9 108.7 ± 8.3 0.225 79.5 ± 3.7 85.9 ± 6.2 0.276
tCho 3.20-3.24 498.3 ± 26.4 551.3 ± 46.8 0.253 344.9 ± 22.3 434.6 ± 44.6 0.075
Taurine 3.40-3.43 242.6 ± 9.6 222.8 ± 12.4 0.393 248.0 ± 8.1 222.3 ± 9.3 0.144
ȕ-Glucose 4.61-4.64 48.4 ± 3.3 49.3 ± 6.0 1.000 63.6 ± 4.3 53.5 ± 6.6 0.172
The values of relative intensities are integrated peak areas from spectra normalized to equal total areas. Wilcoxon rank sum 
tests were used for statistical analyses. *p < 0.05, ** p < 0.01.
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Figure 1 Scores and loadings from multilevel PLS-DA. Separation of treatment and control 
spectra based on (A) the whole data set, (B) 5-year survivors, and (C) non-survivors. The 
variables in the loadings are colored according to VIP scores, indicating the importance of 
each variable in the discrimination. The control spectra equal the difference between pre- and 
post-treatment spectra, while the treatment spectra equal the post-pre treatment difference. 
/DFODFWDWH*O\JO\FLQHȕ-*OFȕ-glucose. 
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Figure 2 PLS-DA of the MR spectra from biopsies excised post-treatment. (A) A score 
plot separating survivors and non-survivors, (B) Representative spectra showing the metabolic 
differences of the tumors of survivors and non-survivors. (C) The loadings of the PLS-DA 
model with variables colored according to the VIP scores. ȕ-*OFȕ-glucose; Lac, lactate, Gly, 
glycine; Cr, creatine; Ala, alanine
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